Antipsychotic

Last updated

Antipsychotic
Drug class
Zyprexa.PNG
Olanzapine, an example of a second-generation (atypical) antipsychotic
Class identifiers
Synonyms Neuroleptics, major tranquilizers [1]
UsePrincipally: Schizophrenia, Schizoaffective disorder, Dementia, Tourette syndrome, Bipolar disorder, irritability in autism spectrum disorder
Clinical data
Drugs.com Drug Classes
External links
MeSH D014150
Legal status
In Wikidata

Antipsychotics, previously known as neuroleptics [1] and major tranquilizers, [2] are a class of psychotropic medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia but also in a range of other psychotic disorders. [3] [4] They are also the mainstay, together with mood stabilizers, in the treatment of bipolar disorder. [5] Moreover, they are also used as adjuncts in the treatment of treatment-resistant major depressive disorder.

Contents

While some research has shown that use of any antipsychotic is associated with smaller brain tissue volumes, [6] [7] including white matter reduction [8] and that this reduction is dose dependent and time dependent, [6] [7] schizophrenia is itself a neurodegenerative disorder associated with reduced brain tissue volumes. [9] A more recent controlled trial suggests that second generation antipsychotics [10] combined with intensive psychosocial therapy [11] may potentially prevent pallidal brain volume loss in first episode psychosis. [12] [8]

The use of antipsychotics may result in many unwanted side effects such as involuntary movement disorders, gynecomastia, impotence, weight gain and metabolic syndrome. Long-term use can produce adverse effects such as tardive dyskinesia, tardive dystonia, and tardive akathisia.

Prevention of these adverse effects is possible through concomitant medication strategies including use of beta-blockers. Currently, treatments for tardive syndromes include VMAT2 inhibitors.

First-generation antipsychotics (e.g., chlorpromazine), known as typical antipsychotics, were first introduced in the 1950s, and others were developed until the early 1970s. [13] Second-generation antipsychotics, known as atypical antipsychotics, arrived with the introduction of clozapine in the early 1970s followed by others (e.g., risperidone). [14] Both generations of medication block receptors in the brain for dopamine, but atypicals block serotonin receptors as well. Third-generation antipsychotics were introduced in the 2000s and offer partial agonism, rather than blockade, of dopamine receptors. [15] Neuroleptic, originating from Greek : νεῦρον (neuron) and λαμβάνω (take hold of)—thus meaning "which takes the nerve"—refers to both common neurological effects and side effects. [16]

Medical uses

Antipsychotics are most frequently used for the following conditions:

Given the limited options available to treat the behavioral problems associated with dementia, other pharmacological and non-pharmacological interventions are usually attempted before using antipsychotics. A risk-to-benefit analysis is performed to weigh the risk of the adverse effects of antipsychotics versus: the potential benefit, the adverse effects of alternative interventions, and the risk of failing to intervene when a patient's behavior becomes unsafe. [20] The same can be said for insomnia, in which they are not recommended as first-line therapy. [20] There are evidence-based indications for using antipsychotics in children (e.g., tic disorder, bipolar disorder, psychosis), but the use of antipsychotics outside of those contexts (e.g., to treat behavioral problems) warrants significant caution. [20]

Antipsychotics are used to treat tics associated with Tourette syndrome. [21] Aripiprazole, an atypical antipsychotic, is used as add-on medication to ameliorate sexual dysfunction as a symptom of selective serotonin reuptake inhibitor antidepressants in women. [22] : 10  Quetiapine is used to treat generalized anxiety disorder. [23]

Schizophrenia

Antipsychotic drug treatment is a key component of schizophrenia treatment recommendations by the National Institute of Health and Care Excellence (NICE), [24] the American Psychiatric Association, [25] and the British Society for Psychopharmacology. [26] The main aim of treatment with antipsychotics is to reduce the positive symptoms of psychosis, that include delusions and hallucinations. [3] There is mixed evidence to support a significant impact of antipsychotic use on primary negative symptoms (such as apathy, lack of emotional affect, and lack of interest in social interactions) or on cognitive symptoms (memory impairments, reduced ability to plan and execute tasks). [27] [28] In general, the efficacy of antipsychotic treatment in reducing positive symptoms appears to increase with the severity of baseline symptoms. [29] All antipsychotic medications work relatively the same way: by antagonizing D2 dopamine receptors. However, there are some differences when it comes to typical and atypical antipsychotics. For example, atypical antipsychotic medications have been seen to lower the neurocognitive impairment associated with schizophrenia more than conventional antipsychotics, although the reasoning and mechanics of this are still unclear to researchers. [30]

Applications of antipsychotic drugs in the treatment of schizophrenia include prophylaxis for those showing symptoms that suggest that they are at high risk of developing psychosis; treatment of first-episode psychosis; maintenance therapy (a form of prophylaxis, maintenance therapy aims to maintain therapeutic benefit and prevent symptom relapse); and treatment of recurrent episodes of acute psychosis. [3] [26]

Prevention of psychosis and symptom improvement

Test batteries such as the PACE (Personal Assessment and Crisis Evaluation Clinic) and COPS (Criteria of Prodromal Syndromes), which measure low-level psychotic symptoms and cognitive disturbances, are used to evaluate people with early, low-level symptoms of psychosis. Test results are combined with family history information to identify patients in the "high-risk" group; they are considered to have a 20–40% risk of progression to frank psychosis within two years. [26] These patients are often treated with low doses of antipsychotic drugs with the goal of reducing their symptoms and preventing progression to frank psychosis. While generally useful for reducing symptoms, clinical trials to date show little evidence that early use of antipsychotics improves long-term outcomes in those with prodromal symptoms, either alone or in combination with cognitive-behavioral therapy. [31]

First-episode psychosis

First-episode psychosis (FEP) is the first time that psychotic symptoms are presented. NICE recommends that all people presenting with first-episode psychosis be treated with both an antipsychotic drug and cognitive behavioral therapy (CBT). NICE further recommends that those expressing a preference for CBT alone be informed that combination treatment is more effective. [24] A diagnosis of schizophrenia is not made at this time as it takes longer to be determined by both DSM-5 and ICD-11, and only around 60% of those presenting with a first episode of psychosis will later be diagnosed with schizophrenia. [32]

The conversion rate for a first episode of drug induced psychosis to bipolar disorder or schizophrenia is lower, with 30% of people converting to either bipolar disorder or schizophrenia. [33] NICE makes no distinction between substance-induced psychosis and any other form of psychosis. The rate of conversion differs for different classes of drugs. [33]

Pharmacological options for the specific treatment of FEP have been discussed in recent reviews. [34] [35] The goals of treatment for FEP include reducing symptoms and potentially improving long-term treatment outcomes. Randomized clinical trials have provided evidence for the efficacy of antipsychotic drugs in achieving the former goal, with first-generation and second generation antipsychotics showing about equal efficacy. The evidence that early treatment has a favorable effect on long-term outcomes is equivocal. [24] [26]

Recurrent psychotic episodes

Placebo-controlled trials of both first- and second-generation antipsychotic drugs consistently demonstrate the superiority of active drugs over placebos in suppressing psychotic symptoms. [26] A large meta-analysis of 38 trials of antipsychotic drugs in schizophrenia with acute psychotic episodes showed an effect size of about 0.5. [36] There is little or no difference in efficacy among approved antipsychotic drugs, including both first- and second-generation agents. [24] [37] The efficacy of such drugs is suboptimal. Few patients achieve complete resolution of symptoms. Response rates, calculated using various cutoff values for symptom reduction, are low, and their interpretation is complicated by high placebo response rates and selective publication of clinical trial results. [38]

Maintenance therapy

The majority of patients treated with an antipsychotic drug will experience a response within four weeks. The goals of continuing treatment are to maintain suppression of symptoms, prevent relapse, improve quality of life, and support engagement in psychosocial therapy. [3] [26]

Maintenance therapy with antipsychotic drugs is clearly superior to placebo in preventing relapse but is associated with weight gain, movement disorders, and high dropout rates. [39] A 3-year trial following persons receiving maintenance therapy after an acute psychotic episode found that 33% obtained long-lasting symptom reduction, 13% achieved remission, and only 27% experienced satisfactory quality of life. The effect of relapse prevention on long term outcomes is uncertain, as historical studies show little difference in long term outcomes before and after the introduction of antipsychotic drugs. [26]

While maintenance therapy clearly reduces the rate of relapses requiring hospitalization, a large observational study in Finland found that, in people that eventually discontinued antipsychotics, the risk of being hospitalized again for a mental health problem or dying increased the longer they were dispensed (and presumably took) antipsychotics prior to stopping therapy. If people did not stop taking antipsychotics, they remained at low risk for relapse and hospitalization compared to those that did. [40] The authors speculated that the difference may be because the people that discontinued treatment after a longer time had more severe mental illness than those that discontinued antipsychotic therapy sooner. [40]

A significant challenge in the use of antipsychotic drugs for the prevention of relapse is the poor rate of adherence. [3] In spite of the relatively high rates of adverse effects associated with these drugs, some evidence, including higher dropout rates in placebo arms compared to treatment arms in randomized clinical trials, suggests that most patients who discontinue treatment do so because of suboptimal efficacy. [39] [41] If someone experiences psychotic symptoms due to nonadherence, they may be compelled to receive treatment through a process called involuntary commitment, in which they can be forced to accept treatment (including antipsychotics). A person can also be committed to treatment outside of a hospital, called outpatient commitment.

Antipsychotics in long-acting injectable (LAI), or "depot", form have been suggested as a method of decreasing medication nonadherence (sometimes also called non-compliance). [3] [42] NICE advises LAIs be offered to patients when preventing covert, intentional nonadherence is a clinical priority. [43] LAIs are used to ensure adherence in outpatient commitment. [3] [44] A meta-analysis found that LAIs resulted in lower rates of rehospitalization with a hazard ratio of 0.83; however, these results were not statistically significant (the 95% confidence interval was 0.62 to 1.11). [42]

Bipolar disorder

Antipsychotics are routinely used, often in conjunction with mood stabilisers such as lithium/valproate, as a first-line treatment for manic and mixed episodes associated with bipolar disorder. [19] [45] The reason for this combination is the therapeutic delay of the aforementioned mood stabilisers (for valproate therapeutic effects are usually seen around five days after treatment is commenced whereas lithium usually takes at least a week [45] before the full therapeutic effects are seen) and the comparatively rapid antimanic effects of antipsychotic drugs. [46] The antipsychotics have a documented efficacy when used alone in acute mania/mixed episodes. [17]

At least five atypical antipsychotics (lumateperone, [47] cariprazine, [48] lurasidone, [49] olanzapine, [50] and quetiapine [51] ) have also been found to possess efficacy in the treatment of bipolar depression as a monotherapy, whereas only olanzapine [52] and quetiapine [53] [54] have been proven to be effective broad-spectrum (i.e., against all three types of relapse—manic, mixed and depressive) prophylactic (or maintenance) treatments in patients with bipolar disorder. A recent Cochrane review also found that olanzapine had a less favourable risk/benefit ratio than lithium as a maintenance treatment for bipolar disorder. [55]

The American Psychiatric Association and the UK National Institute for Health and Care Excellence recommend antipsychotics for managing acute psychotic episodes in schizophrenia or bipolar disorder, and as a longer-term maintenance treatment for reducing the likelihood of further episodes. [56] [57] They state that response to any given antipsychotic can be variable so that trials may be necessary, and that lower doses are to be preferred where possible. A number of studies have looked at levels of "compliance" or "adherence" with antipsychotic regimes and found that discontinuation (stopping taking them) by patients is associated with higher rates of relapse, including hospitalization.

Dementia

Psychosis and agitation develop in as many as 80 percent of people living in nursing homes. [58] Despite a lack of FDA approval and black-box warnings, atypical antipsychotics are very often prescribed to people with dementia. [58] An assessment for an underlying cause of behavior is needed before prescribing antipsychotic medication for symptoms of dementia. [59] Antipsychotics in old age dementia showed a modest benefit compared to placebo in managing aggression or psychosis, but this is combined with a fairly large increase in serious adverse events. Thus, antipsychotics should not be used routinely to treat dementia with aggression or psychosis, but may be an option in a few cases where there is severe distress or risk of physical harm to others. [60] Psychosocial interventions may reduce the need for antipsychotics. [61] In 2005, the FDA issued an advisory warning of an increased risk of death when atypical antipsychotics are used in dementia. [58] In the subsequent 5 years, the use of atypical antipsychotics to treat dementia decreased by nearly 50%. [58]

Major depressive disorder

A number of atypical antipsychotics have some benefits when used in addition to other treatments in major depressive disorder. [62] [63] Aripiprazole, quetiapine extended-release, and olanzapine (when used in conjunction with fluoxetine) have received the Food and Drug Administration (FDA) labelling for this indication. [64] There is, however, a greater risk of side effects with their use compared to using traditional antidepressants. [62] The greater risk of serious side effects with antipsychotics is why, e.g., quetiapine was denied approval as monotherapy for major depressive disorder or generalized anxiety disorder, and instead was only approved as an adjunctive treatment in combination with traditional antidepressants. [65]

A recent study on the use of antipychotics in unipolar depression concluded that the use of those drugs in addition to antidepressants alone leads to a worse disease outcome. This effect is especially pronounced in younger patients with psychotic unipolar depression. Considering the wide use of such combination therapies, further studies on the side effects of antipychotics as an add-on therapy are warranted. [66]

Other

Global antipsychotic utilization has seen a steady growth since the introduction of atypical (second-generation) antipsychotics and this is ascribed to off-label use for many other unapproved disorders. [67] [68] [69] Besides the above uses antipsychotics may be used for obsessive–compulsive disorder, post-traumatic stress disorder, personality disorders, Tourette syndrome, autism and agitation in those with dementia. [70] Evidence however does not support the use of atypical antipsychotics in eating disorders or personality disorder. [71] The atypical antipsychotic risperidone may be useful for obsessive–compulsive disorder. [70] The use of low doses of antipsychotics for insomnia, while common, is not recommended as there is little evidence of benefit as well as concern regarding adverse effects. [71] [72] Some of the more serious adverse effects may also occur at the low doses used, such as dyslipidemia and neutropenia, [73] [74] and a recent network meta-analysis of 154 double-blind, randomized controlled trials of drug therapies vs. placebo for insomnia in adults found that quetiapine did not demonstrated any short-term benefits in sleep quality. [75] Low dose antipsychotics may also be used in treatment of impulse-behavioural and cognitive-perceptual symptoms of borderline personality disorder. [76] Despite the lack of evidence supporting the benefit of antipsychotics in people with personality disorders, 1 in 4 who do not have a serious mental illness are prescribed them in UK primary care. Many people receive these medication for over a year, contrary to NICE guidelines. [77] [78]

In children they may be used in those with disruptive behavior disorders, mood disorders and pervasive developmental disorders or intellectual disability. [79] Antipsychotics are only weakly recommended for Tourette syndrome, because although they are effective, side effects are common. [80] The situation is similar for those on the autism spectrum. [81] Much of the evidence for the off-label use of antipsychotics (for example, for dementia, OCD, PTSD, personality disorders, Tourette's) was of insufficient scientific quality to support such use, especially as there was strong evidence of increased risks of stroke, tremors, significant weight gain, sedation, and gastrointestinal problems. [82] A UK review of unlicensed usage in children and adolescents reported a similar mixture of findings and concerns. [83] A survey of children with pervasive developmental disorder found that 16.5% were taking an antipsychotic drug, most commonly for irritability, aggression, and agitation. Both risperidone and aripiprazole have been approved by the US FDA for the treatment of irritability in autistic children and adolescents. [84] A review in the UK found that the use of antipsychotics in England doubled between 2000 and 2019. Children were prescribed antipsychotics for conditions for which there is no approval, such as autism. [85] [86]

Aggressive challenging behavior in adults with intellectual disability is often treated with antipsychotic drugs despite lack of an evidence base. A recent randomized controlled trial, however, found no benefit over placebo and recommended that the use of antipsychotics in this way should no longer be regarded as an acceptable routine treatment. [87]

Antipsychotics may be an option, together with stimulants, in people with ADHD and aggressive behavior when other treatments have not worked. [88] They have not been found to be useful for the prevention of delirium among those admitted to hospital. [89]

Typicals vs atypicals

Aside from reduced extrapyramidal symptoms, and with the clear exception of clozapine, it is unclear whether the atypical (second-generation) antipsychotics offer advantages over older, first generation antipsychotics. [3] [28] [90] Amisulpride, olanzapine, risperidone and clozapine may be more effective but are associated with greater side effects. [91] Typical antipsychotics have equal drop-out and symptom relapse rates to atypicals when used at low to moderate dosages. [92]

Clozapine is an effective treatment for those who respond poorly to other drugs ("treatment-resistant" or "refractory" schizophrenia), [93] but it has the potentially serious side effect of agranulocytosis (lowered white blood cell count) in less than 4% of people. [94]

Due to bias in the research the accuracy of comparisons of atypical antipsychotics is a concern. [95]

In 2005, a US government body, the National Institute of Mental Health published the results of a major independent study (the CATIE project). [96] No other atypical studied (risperidone, quetiapine, and ziprasidone) did better than the first-generation antipsychotic perphenazine on the measures used, nor did they produce fewer adverse effects than the typical antipsychotic perphenazine, although more patients discontinued perphenazine owing to extrapyramidal effects compared to the atypical agents (8% vs. 2% to 4%). [17] This is significant because any patient with tardive dyskinesia was specifically excluded from randomization to perphenazine; i.e., in the CATIE study the patient cohort randomized to receive perphenazne was at lower risk of having extrapyramidal symptoms. [97]

Atypical antipsychotics do not appear to lead to improved rates of medication adherence compared to typical antipsychotics. [98]

Many researchers question the first-line prescribing of atypicals over typicals, and some even question the distinction between the two classes. [99] [100] [101] In contrast, other researchers point to the significantly higher risk of tardive dyskinesia and other extrapyramidal symptoms with the typicals and for this reason alone recommend first-line treatment with the atypicals, notwithstanding a greater propensity for metabolic adverse effects in the latter. [102] The UK government organization NICE recently revised its recommendation favoring atypicals, to advise that the choice should be an individual one based on the particular profiles of the individual drug and on the patient's preferences.

The re-evaluation of the evidence has not necessarily slowed the bias toward prescribing the atypicals. [103]

Adverse effects

Generally, more than one antipsychotic drug should not be used at a time because of increased adverse effects. [104]

Some atypicals are associated with considerable weight gain, diabetes and the risk of metabolic syndrome. [105] Unwanted side effects cause people to stop treatment, resulting in relapses. [106] Risperidone (atypical) has a similar rate of extrapyramidal symptoms to haloperidol (typical). [105] A rare but potentially lethal condition of neuroleptic malignant syndrome (NMS) has been associated with the use of antipsychotics. Through its early recognition, and timely intervention rates have declined. However, an awareness of the syndrome is advised to enable intervention. [107] Another less rare condition of tardive dyskinesia can occur due to long-term use of antipsychotics, developing after months or years of use. It is more often reported with use of typical antipsychotics. [108] Very rarely antipsychotics may cause tardive psychosis. [109]

Clozapine is associated with side effects that include weight gain, tiredness, and hypersalivation. More serious adverse effects include seizures, NMS, neutropenia, and agranulocytosis (lowered white blood cell count) and its use needs careful monitoring. [110] [111]

Clozapine is also associated with thromboembolism (including pulmonary embolism), myocarditis, and cardiomyopathy. [112] [113] A systematic review of clozapine-associated pulmonary embolism indicates that this adverse effect can often be fatal, and that it has an early onset, and is dose-dependent. The findings advised the consideration of using a prevention therapy for venous thromboembolism after starting treatment with clozapine, and continuing this for six months. [113] Constipation is three times more likely to occur with the use of clozapine, and severe cases can lead to ileus and bowel ischemia resulting in many fatalities. [110] Very rare clozapine adverse effects include periorbital edema due to several possible mechanisms (e.g., inhibition of platelet-derived growth factor receptors leading to increased vascular permeability, antagonism of renal dopamine receptors with electrolyte and fluid imbalance and immune-mediated hypersensitivity reactions). [114]

However, the risk of serious adverse effects from clozapine is low, and there are the beneficial effects to be gained of a reduced risk of suicide, and aggression. [115] [116] Typical antipsychotics and atypical risperidone can have a side effect of sexual dysfunction. [117] Clozapine, olanzapine, and quetiapine are associated with beneficial effects on sexual functioning helped by various psychotherapies. [118]

By rate

Common (≥ 1% and up to 50% incidence for most antipsychotic drugs) adverse effects of antipsychotics include: [119]

- Akathisia, an often distressing sense of inner restlessness.
- Dystonia, an abnormal muscle contraction
- Pseudoparkinsonism, symptoms that are similar to what people with Parkinson's disease experience, including tremulousness and drooling
- Galactorrhoea, the unusual secretion of breast milk.
- Gynaecomastia, abnormal growth of breast tissue
- Sexual dysfunction (in both sexes)
- Osteoporosis
- Blurred vision
- Constipation
- Dry mouth (although hypersalivation may also occur)
- Reduced perspiration

Rare/Uncommon (<1% incidence for most antipsychotic drugs) adverse effects of antipsychotics include:

- Causing weight gain by antagonizing the histamine H1 and serotonin 5-HT2C receptors [124] and perhaps by interacting with other neurochemical pathways in the central nervous system. [125]
- Autonomic instability, which can manifest with tachycardia, nausea, vomiting, diaphoresis, etc.
- Hyperthermia — elevated body temperature.
- Mental status change (confusion, hallucinations, coma, etc.)
- Muscle rigidity
- Laboratory abnormalities (e.g., elevated creatine kinase, reduced iron plasma levels, electrolyte abnormalities, etc.)

Long-term effects

Some studies have found decreased life expectancy associated with the use of antipsychotics, and argued that more studies are needed. [127] [128] Antipsychotics may also increase the risk of early death in individuals with dementia. [129] Antipsychotics typically worsen symptoms in people with depersonalisation disorder. [130] Antipsychotic polypharmacy (prescribing two or more antipsychotics at the same time for an individual) is a common practice but not evidence-based or recommended, and there are initiatives to curtail it. [104] [131] Similarly, the use of excessively high doses (often the result of polypharmacy) continues despite clinical guidelines and evidence indicating that it is usually no more effective but is usually more harmful. [104] [132] A meta-analysis of observational studies with over two million individuals has suggested a moderate association of antipsychotic use with breast cancer. [133]

Loss of grey matter and other brain structural changes over time are observed amongst people diagnosed with schizophrenia. Meta-analyses of the effects of antipsychotic treatment on grey matter volume and the brain's structure have reached conflicting conclusions. A 2012 meta-analysis concluded that grey matter loss is greater in patients treated with first generation antipsychotics relative to those treated with atypicals, and hypothesized a protective effect of atypicals as one possible explanation. [134] A second meta-analysis suggested that treatment with antipsychotics was associated with increased grey matter loss. [135] Animal studies found that monkeys exposed to both first- and second-generation antipsychotics experience significant reduction in brain volume, resulting in an 8-11% reduction in brain volume over a 17–27 month period. [136]

The National Association of State Mental Health Program Directors said that antipsychotics are not interchangeable and it is recommend including trying at least one weight-neutral treatment for those patients with potential metabolic issues. [137]

Subtle, long-lasting forms of akathisia are often overlooked or confused with post-psychotic depression, in particular when they lack the extrapyramidal aspect that psychiatrists have been taught to expect when looking for signs of akathisia. [138]

Adverse effect on cognitive function [139] [140] [141] and increased risk of death in people with dementia along with worsening of symptoms has been described in the literature. [142] [143]

Discontinuation

The British National Formulary recommends a gradual withdrawal when discontinuing antipsychotics to avoid acute withdrawal syndrome or rapid relapse. [144] Symptoms of withdrawal commonly include nausea, vomiting, and loss of appetite. [145] Other symptoms may include restlessness, increased sweating, and trouble sleeping. [145] Less commonly there may be a feeling of the world spinning, numbness, or muscle pains. [145] Symptoms generally resolve after a short period of time. [145]

There is tentative evidence that discontinuation of antipsychotics can result in psychosis. [146] It may also result in recurrence of the condition that is being treated. [147] Rarely tardive dyskinesia can occur when the medication is stopped. [145]

Unexpected psychotic episodes have been observed in patients withdrawing from clozapine. This is referred to as supersensitivity psychosis, not to be equated with tardive dyskinesia. [146] [148]

Tardive dyskinesia may abate during withdrawal from the antipsychotic agent, or it may persist. [149]

Withdrawal effects may also occur when switching a person from one antipsychotic to another, (it is presumed due to variations of potency and receptor activity). Such withdrawal effects can include cholinergic rebound, an activation syndrome, and motor syndromes including dyskinesias. These adverse effects are more likely during rapid changes between antipsychotic agents, so making a gradual change between antipsychotics minimises these withdrawal effects. [150] The British National Formulary recommends a gradual withdrawal when discontinuing antipsychotic treatment to avoid acute withdrawal syndrome or rapid relapse. [151] The process of cross-titration involves gradually increasing the dose of the new medication while gradually decreasing the dose of the old medication.

City and Hackney Clinical Commissioning Group found more than 1,000 patients in their area in July 2019 who had not had regular medication reviews or health checks because they were not registered as having serious mental illness. On average they had been taking these drugs for six years. If this is typical of practice in England more than 100,000 patients are probably in the same position. [152]

List of agents

Chlorpromazine Chlorpromazine.svg
Chlorpromazine
Haloperidol Haloperidol.svg
Haloperidol
Quetiapine Quetiapine.svg
Quetiapine

Clinically used antipsychotic medications are listed below by drug group. Trade names appear in parentheses. A 2013 review has stated that the division of antipsychotics into first and second generation is perhaps not accurate. [37]

Notes:

† indicates drugs that are no longer (or were never) marketed in English-speaking countries.

‡ denotes drugs that are no longer (or were never to begin with) marketed in the United States. Some antipsychotics are not firmly placed in either first-generation or second-generation classes.

# denotes drugs that have been withdrawn worldwide.

First-generation (typical)

Butyrophenones

Diphenylbutylpiperidines

Phenothiazines

Thioxanthenes

Disputed/unknown

This category is for drugs that have been called both first and second-generation, depending on the literature being used.

Benzamides

Tricyclics

Others

Second-generation (atypical)

Benzamides

  • Amisulpride (Socian) ‡ – Selective dopamine antagonist. Higher doses (greater than 400 mg) act upon post-synaptic dopamine receptors resulting in a reduction in the positive symptoms of schizophrenia, such as psychosis. Lower doses, however, act upon dopamine autoreceptors, resulting in increased dopamine transmission, improving the negative symptoms of schizophrenia. Lower doses of amisulpride have also been shown to have antidepressant and anxiolytic effects in non-schizophrenic patients, leading to its use in dysthymia and social phobias.
  • Nemonapride † – Used in Japan.
  • Remoxipride # – Has a risk of causing aplastic anaemia and, hence, has been withdrawn from the market worldwide. It has also been found to possess relatively low (virtually absent) potential to induce hyperprolactinaemia and extrapyramidal symptoms, likely attributable to its comparatively weak binding to (and, hence, rapid dissociation from) the D2 receptor. [153]
  • Sultopride – An atypical antipsychotic of the benzamide chemical class used in Europe, Japan, and Hong Kong for the treatment of schizophrenia. It was launched by Sanofi-Aventis in 1976. Sultopride acts as a selective D2 and D3 receptor antagonist.

Benzisoxazoles/benzisothiazoles

  • Iloperidone (Fanapt) – Approved by the US FDA in 2009, it is fairly well tolerated, although hypotension, dizziness, and somnolence were very common side effects. Has not received regulatory approval in other countries, however.
  • Paliperidone (Invega) – Primary, active metabolite of risperidone that was approved in 2006.
  • Perospirone † – Has a higher incidence of extrapyramidal side effects than other atypical antipsychotics. [154]
  • Risperidone (Risperdal) – Divided dosing is recommended until initial titration is completed, at which time the drug can be administered once daily. Used off-label to treat Tourette syndrome and anxiety disorder.
  • Ziprasidone (Geodon) – Approved in 2004 [155] to treat bipolar disorder. Side-effects include a prolonged QT interval in the heart, which can be dangerous for patients with heart disease or those taking other drugs that prolong the QT interval.
  • Lurasidone (Latuda) – Approved by the US FDA for schizophrenia and bipolar depression, and for use as schizophrenia treatment in Canada.

Butyrophenones

  • Melperone † – Only used in a few European countries. No English-speaking country has licensed it to date.
  • Lumateperone (Caplyta)

Tricyclics

  • Asenapine (Saphris) – Of the dibenzo-oxepino pyrrole class of atypical antipsychotics. Used for the treatment of schizophrenia and acute mania associated with bipolar disorder.
  • Clozapine (Clozaril) – Of the dibenzodiazepine class of atypical antipsychotics. Requires routine laboratory monitoring of complete blood counts every one to four weeks due to the risk of agranulocytosis. It has unparalleled efficacy in the treatment of treatment-resistant schizophrenia.
  • Olanzapine (Zyprexa) – Of the theienobenzodiazepine class of atypical antipsychotics. Used to treat psychotic disorders including schizophrenia, acute manic episodes, and maintenance of bipolar disorder. Used as an adjunct to antidepressant therapy, either alone or in combination with fluoxetine as Symbyax.
  • Quetiapine (Seroquel) – Of the dibenzothiazepine class of atypical antipsychotics. Used primarily to treat bipolar disorder and schizophrenia. Also used and licensed in a few countries (including Australia, the United Kingdom and the United States) as an adjunct to antidepressant therapy in patients with major depressive disorder. It's the only antipsychotic that's demonstrated efficacy as a monotherapy for the treatment of major depressive disorder and bipolar disorder (it treats mixed mood swings alone). It indirectly serves as a norepinephrine reuptake inhibitor by means of its active metabolite, norquetiapine.
  • Zotepine – Of the dibenzothiepin class of atypical antipsychotic indicated for acute and chronic schizophrenia. It is still used in Japan and was once used in Germany but it was discontinued.†

Others

  • Blonanserin – Approved by the PMDA in 2008. Used in Japan and South Korea.
  • Pimavanserin – A selective 5-HT2A receptor antagonist approved for the treatment of Parkinson's disease psychosis in 2016.
  • Sertindole ‡ – Developed by the Danish pharmaceutical company H. Lundbeck. Like the other atypical antipsychotics, it is believed to have antagonist activity at dopamine and serotonin receptors in the brain.

Third-generation

Third generation antipsychotics are recognized as demonstrating D2 receptor partial agonism [156] as opposed to the D2 and 5HT-2A receptor antagonism of second-generation (atypical) antipsychotics and D2 antagonism of first-generation (typical) antipsychotics. [15]

Benzisoxazoles/benzisothiazoles

  • Lumateperone (Caplyta) – In December 2019, lumateperone, a presynaptic D2 receptor partial agonist and postsynaptic D2 receptor antagonist, received its first global approval in the USA for the treatment of schizophrenia in adults. [157] In 2020 and 2021 FDA approved for depressive episodes associated with bipolar I or II disorder in adults, as monotherapy and as adjunctive therapy with lithium or valproate.

Phenylpiperazines/quinolinones

  • Aripiprazole (Abilify) - Partial agonist at the D2 receptor. Considered the prototypical third-generation antipsychotic. [158]
  • Aripiprazole lauroxil (Abilify Maintena) – Long-acting version of aripiprazole for injection.
  • Brexpiprazole (Rexulti) – Partial agonist of the D2 receptor. Successor of aripiprazole.
  • Cariprazine (Vraylar, Reagila) – A D3-preferring D2/3 partial agonist.

Phenylpiperazines/benzoxazinones

  • Brilaroxazine – A D2/3/4 and 5-HT1A partial agonist and 5-HT2A/2B/7 antagonist

Mechanism of action

Antipsychotic drugs such as haloperidol and chlorpromazine tend to block dopamine D2 receptors in the dopaminergic pathways of the brain. This means that dopamine released in these pathways has less effect. Excess release of dopamine in the mesolimbic pathway has been linked to psychotic experiences. Decreased dopamine release in the prefrontal cortex, and excess dopamine release in other pathways, are associated with psychotic episodes in schizophrenia and bipolar disorder. [159] [160]

In addition to the antagonistic effects of dopamine, antipsychotics (in particular atypical neuroleptics) also antagonize 5-HT2A receptors. Different alleles of the 5-HT2A receptor have been associated with schizophrenia and other psychoses, including depression. [161] [162] Higher concentrations of 5-HT2A receptors in cortical and subcortical areas, in particular in the right caudate nucleus have been historically recorded. [161]

Typical antipsychotics are not particularly selective and also block dopamine receptors in the mesocortical pathway, tuberoinfundibular pathway, and the nigrostriatal pathway. Blocking D2 receptors in these other pathways is thought to produce some unwanted side effects that the typical antipsychotics can produce (see above). They were commonly classified on a spectrum of low potency to high potency, where potency referred to the ability of the drug to bind to dopamine receptors, and not to the effectiveness of the drug. High-potency antipsychotics such as haloperidol, in general, have doses of a few milligrams and cause less sleepiness and calming effects than low-potency antipsychotics such as chlorpromazine and thioridazine, which have dosages of several hundred milligrams. The latter have a greater degree of anticholinergic and antihistaminergic activity, which can counteract dopamine-related side-effects. [163]

Atypical antipsychotic drugs have a similar blocking effect on D2 receptors; however, most also act on serotonin receptors, especially 5-HT2A and 5-HT2C receptors. Both clozapine and quetiapine appear to bind just long enough to elicit antipsychotic effects but not long enough to induce extrapyramidal side effects and prolactin hypersecretion. [164] 5-HT2A antagonism increases dopaminergic activity in the nigrostriatal pathway, leading to a lowered extrapyramidal side effect liability among the atypical antipsychotics. [164] [165]

Through the ability of most antipsychotics to antagonize 5-HT2A serotonin pathways enabling a sensitisation of postsynaptic serotonin receptors, MDMA exposure can be more intense because it has more excitatory receptors to activate. The same effect can be observed with the D2 antagonizing with normal amphetamine (with this just being hypothetical as there is the fact that antipsychotics sensitize receptors, [166] with exact these postsynaptic receptors (5-HT2A, D2) being flooded by the respective neurotransmitter (serotonine, dopamine) from amphetamine exposure). [167] [168]

Comparison of medications

Pharmacokinetics of long-acting injectable antipsychotics
MedicationBrand nameClassVehicleDosageTmaxt1/2 singlet1/2 multiplelogPcRef
Aripiprazole lauroxil Aristada Atypical Water a441–1064 mg/4–8 weeks24–35 days ?54–57 days7.9–10.0
Aripiprazole monohydrate Abilify Maintena Atypical Water a300–400 mg/4 weeks7 days ?30–47 days4.9–5.2
Bromperidol decanoate Impromen Decanoas Typical Sesame oil 40–300 mg/4 weeks3–9 days ?21–25 days7.9 [253]
Clopentixol decanoate Sordinol Depot Typical Viscoleo b50–600 mg/1–4 weeks4–7 days ?19 days9.0 [254]
Flupentixol decanoate Depixol Typical Viscoleo b10–200 mg/2–4 weeks4–10 days8 days17 days7.2–9.2 [254] [255]
Fluphenazine decanoate Prolixin Decanoate Typical Sesame oil 12.5–100 mg/2–5 weeks1–2 days1–10 days14–100 days7.2–9.0 [256] [257] [258]
Fluphenazine enanthate Prolixin Enanthate Typical Sesame oil 12.5–100 mg/1–4 weeks2–3 days4 days ?6.4–7.4 [257]
Fluspirilene Imap, Redeptin Typical Water a2–12 mg/1 week1–8 days7 days ?5.2–5.8 [259]
Haloperidol decanoate Haldol Decanoate Typical Sesame oil 20–400 mg/2–4 weeks3–9 days18–21 days7.2–7.9 [260] [261]
Olanzapine pamoate Zyprexa Relprevv Atypical Water a150–405 mg/2–4 weeks7 days ?30 days–
Oxyprothepin decanoate Meclopin Typical  ? ? ? ? ?8.5–8.7
Paliperidone palmitate Invega Sustenna Atypical Water a39–819 mg/4–12 weeks13–33 days25–139 days ?8.1–10.1
Perphenazine decanoate Trilafon Dekanoat Typical Sesame oil 50–200 mg/2–4 weeks ? ?27 days8.9
Perphenazine enanthate Trilafon Enanthate Typical Sesame oil 25–200 mg/2 weeks2–3 days ?4–7 days6.4–7.2 [262]
Pipotiazine palmitate Piportil Longum Typical Viscoleo b25–400 mg/4 weeks9–10 days ?14–21 days8.5–11.6 [255]
Pipotiazine undecylenate Piportil Medium Typical Sesame oil 100–200 mg/2 weeks ? ? ?8.4
Risperidone Risperdal Consta Atypical Microspheres 12.5–75 mg/2 weeks21 days ?3–6 days–
Zuclopentixol acetate Clopixol Acuphase Typical Viscoleo b50–200 mg/1–3 days1–2 days1–2 days4.7–4.9
Zuclopentixol decanoate Clopixol Depot Typical Viscoleo b50–800 mg/2–4 weeks4–9 days ?11–21 days7.5–9.0
Note: All by intramuscular injection. Footnotes:a = Microcrystalline or nanocrystalline aqueous suspension. b = Low-viscosity vegetable oil (specifically fractionated coconut oil with medium-chain triglycerides). c = Predicted, from PubChem and DrugBank. Sources:Main: See template.

History

Advertisement for Thorazine (chlorpromazine) from the 1950s, reflecting the perceptions of psychosis, including the now-discredited perception of a tendency towards violence, from the time when antipsychotics were discovered Thorazine advert.jpg
Advertisement for Thorazine (chlorpromazine) from the 1950s, reflecting the perceptions of psychosis, including the now-discredited perception of a tendency towards violence, from the time when antipsychotics were discovered

The original antipsychotic drugs were happened upon largely by chance and then tested for their effectiveness. The first, chlorpromazine, was developed as a surgical anesthetic. It was first used on psychiatric patients because of its powerful calming effect; at the time it was regarded as a non-permanent "pharmacological lobotomy". [264] Lobotomy at the time was used to treat many behavioral disorders, including psychosis, although its effect was to markedly reduce behavior and mental functioning of all types. However, chlorpromazine proved to reduce the effects of psychosis in a more effective and specific manner than lobotomy, even though it was known to be capable of causing severe sedation. The underlying neurochemistry involved has since been studied in detail, and subsequent antipsychotic drugs have been developed by rational drug design.

The discovery of chlorpromazine's psychoactive effects in 1952 led to further research that resulted in the development of antidepressants, anxiolytics, and the majority of other drugs now used in the management of psychiatric conditions. In 1952, Henri Laborit described chlorpromazine only as inducing indifference towards what was happening around them in nonpsychotic, nonmanic patients, and Jean Delay and Pierre Deniker described it as controlling manic or psychotic agitation. The former claimed to have discovered a treatment for agitation in anyone, and the latter team claimed to have discovered a treatment for psychotic illness. [265]

Until the 1970s there was considerable debate within psychiatry on the most appropriate term to use to describe the new drugs. [16] In the late 1950s the most widely used term was "neuroleptic", followed by "major tranquilizer" and then "ataraxic". [16] The first recorded use of the term tranquilizer dates from the early nineteenth century. [266] In 1953 Frederik F. Yonkman, a chemist at the Swiss-based Cibapharmaceutical company, first used the term tranquilizer to differentiate reserpine from the older sedatives. [267] The word neuroleptic was coined in 1955 by Delay and Deniker after their discovery (1952) of the antipsychotic effects of chlorpromazine. [16] It is derived from the Greek : "νεῦρον" (neuron, originally meaning "sinew" but today referring to the nerves) and "λαμβάνω" (lambanō, meaning "take hold of"). Thus, the word means taking hold of one's nerves. It was often taken to refer also to common side effects such as reduced activity in general, as well as lethargy and impaired motor control. Although these effects are unpleasant and in some cases harmful, they were at one time, along with akathisia, considered a reliable sign that the drug was working. [264] The term "ataraxy" was coined by the neurologist Howard Fabing and the classicist Alister Cameron to describe the observed effect of psychic indifference and detachment in patients treated with chlorpromazine. [268] This term derived from the Greek adjective "ἀτάρακτος" ( ataraktos ), which means "not disturbed, not excited, without confusion, steady, calm". [16] In the use of the terms "tranquilizer" and "ataractic", medical practitioners distinguished between the "major tranquilizers" or "major ataractics", which referred to drugs used to treat psychoses, and the "minor tranquilizers" or "minor ataractics", which referred to drugs used to treat neuroses. [16] While popular during the 1950s, these terms are infrequently used today. They are being abandoned in favor of "antipsychotic", which refers to the drug's desired effects. [16] Today, "minor tranquilizer" can refer to anxiolytic and/or hypnotic drugs such as the benzodiazepines and nonbenzodiazepines, which are useful as generally short-term management for insomnia together with cognitive behavioral therapy for insomnia. [269] [270] They are potentially addictive sedatives.

Antipsychotics are broadly divided into two groups, the typical or first-generation antipsychotics and the atypical or second-generation antipsychotics. The difference between first- and second-generation antipsychotics is a subject of debate. The second-generation antipsychotics are generally distinguishable by the presence of 5HT2A receptor antagonism and a corresponding lower propensity for extrapyramidal side effects compared to first-generation antipsychotics. [16]

Society and culture

Terminology

The term major tranquilizer was used for older antipsychotic drugs. The term neuroleptic is often used as a synonym for antipsychotic, even though – strictly speaking – the two terms are not interchangeable. Antipsychotic drugs are a subgroup of neuroleptic drugs, because the latter have a wider range of effects. [271] [272]

Antipsychotics are a type of psychoactive or psychotropic medication. [273] [274]

Sales

Antipsychotics were once among the biggest selling and most profitable of all drugs, generating $22 billion in global sales in 2008. [275] By 2003 in the US, an estimated 3.21 million patients received antipsychotics, worth an estimated $2.82 billion. Over 2/3 of prescriptions were for the newer, more expensive atypicals, each costing on average $164 per year, compared to $40 for the older types. [276] By 2008, sales in the US reached $14.6 billion, the biggest selling drugs in the US by therapeutic class. [277]

In the five years since July 2017 the number of antipsychotic medicines dispensed in the community in the United Kingdom has increased by 11.2%. There have also been substantial price rises. Risperidone 6 mg tablets, the largest, increased from £3.09 in July 2017 to £41.16 in June 2022. The NHS is spending an additional £33 million annually on antipsychotics. Haloperidol 500 microgram tablets constituted £14.3 million of this. [278]

Overprescription

Antipsychotics in the nursing home population are often overprescribed, often for the purposes of making it easier to handle dementia patients. Federal efforts to reduce the use of antipsychotics in US nursing homes has led to a nationwide decrease in their usage in 2012. [279] [280] [281]

Antipsychotics are sometimes administered as part of compulsory psychiatric treatment via inpatient (hospital) commitment or outpatient commitment.

Formulations

They may be administered orally or, in some cases, through long-acting (depot) injections administered in the dorsgluteal, ventrogluteal or deltoid muscle. Short-acting parenteral formulations also exist, which are generally reserved for emergencies or when oral administration is otherwise impossible. The oral formulations include immediate release, extended release, and orally disintegrating products (which are not sublingual, and can help ensure that medications are swallowed instead of "cheeked"). Sublingual products (e.g., asenapine) also exist, which must be held under the tongue for absorption. The first transdermal formulation of an antipsychotic (transdermal asenapine, marketed as Secuado), was FDA-approved in 2019. [282]

Recreational use

Certain second-generation antipsychotics are misused or abused for their sedative, tranquilizing, and (paradoxically) "hallucinogenic" effects. [283] The most commonly implicated second-generation antipsychotic is quetiapine. [283] In case reports, quetiapine has been abused in doses taken by mouth (which is how the drug is available from the manufacturer), but also crushed and insufflated or mixed with water for injection into a vein. [283] Olanzapine, another sedating second-generation antipsychotic, has also been misused for similar reasons. [283] There is no standard treatment for antipsychotic abuse, though switching to a second-generation antipsychotic with less abuse potential (e.g., aripiprazole) has been used. [283]

Controversy

Joanna Moncrieff has argued that antipsychotic drug treatment is often undertaken as a means of control rather than to treat specific symptoms experienced by the patient. [284]

Use of this class of drugs has a history of criticism in residential care. As the drugs used can make patients calmer and more compliant, critics claim that the drugs can be overused. Outside doctors can feel under pressure from care home staff. [285] In an official review commissioned by UK government ministers it was reported that the needless use of antipsychotic medication in dementia care was widespread and was linked to 1800 deaths per year. [286] [287] In the US, the government has initiated legal action against the pharmaceutical company Johnson & Johnson for allegedly paying kickbacks to Omnicare to promote its antipsychotic risperidone (Risperdal) in nursing homes. [288]

There has also been controversy about the role of pharmaceutical companies in marketing and promoting antipsychotics, including allegations of downplaying or covering up adverse effects, expanding the number of conditions or illegally promoting off-label usage; influencing drug trials (or their publication) to try to show that the expensive and profitable newer atypicals were superior to the older cheaper typicals that were out of patent. Following charges of illegal marketing, settlements by two large pharmaceutical companies in the US set records for the largest criminal fines ever imposed on corporations. [289] One case involved Eli Lilly and Company's antipsychotic Zyprexa, and the other involved Bextra. In the Bextra case, the government also charged Pfizer with illegally marketing another antipsychotic, Geodon. [289] In addition, AstraZeneca faces numerous personal-injury lawsuits from former users of Seroquel (quetiapine), amidst federal[ clarification needed ] investigations of its marketing practices. [290] By expanding the conditions for which they were indicated, Astrazeneca's Seroquel and Eli Lilly's Zyprexa had become the biggest selling antipsychotics in 2008 with global sales of $5.5 billion and $5.4 billion respectively. [275]

Harvard University medical professor Joseph Biederman conducted research on bipolar disorder in children that led to an increase in such diagnoses. A 2008 Senate[ which? ] investigation found that Biederman also received $1.6 million in speaking and consulting fees between 2000 and 2007, some of them undisclosed to Harvard, from companies including makers of antipsychotic drugs prescribed for children with bipolar disorder. Johnson & Johnson gave more than $700,000 to a research center that was headed by Biederman from 2002 to 2005, where research was conducted, in part, on Risperdal, the company's antipsychotic drug. Biederman has responded saying that the money did not influence him and that he did not promote a specific diagnosis or treatment. [289]

Pharmaceutical companies have also been accused of attempting to set the mental health agenda through activities such as funding consumer advocacy groups. [291]

Special populations

It is recommended that persons with dementia who exhibit behavioral and psychological symptoms should not be given antipsychotics before trying other treatments. [292] [ needs update ] When taking antipsychotics this population has increased risk of cerebrovascular effects, parkinsonism or extrapyramidal symptoms, sedation, confusion and other cognitive adverse effects, weight gain, and increased mortality. [292] Physicians and caretakers of persons with dementia should try to address symptoms including agitation, aggression, apathy, anxiety, depression, irritability, and psychosis with alternative treatments whenever antipsychotic use can be replaced or reduced. [292] Elderly persons often have their dementia treated first with antipsychotics and this is not the best management strategy. [293]

See also

Notes

  1. ↑ Bolded drug names indicate drugs that are metabolites of clinically-marketed antipsychotics.

Related Research Articles

<span class="mw-page-title-main">Mood stabilizer</span> Psychiatric medication used to treat mood disorders

A mood stabilizer is a psychiatric medication used to treat mood disorders characterized by intense and sustained mood shifts, such as bipolar disorder and the bipolar type of schizoaffective disorder.

Psychosis is a condition of the mind that results in difficulties determining what is real and what is not real. Symptoms may include delusions and hallucinations, among other features. Additional symptoms are incoherent speech and behavior that is inappropriate for a given situation. There may also be sleep problems, social withdrawal, lack of motivation, and difficulties carrying out daily activities. Psychosis can have serious adverse outcomes.

<span class="mw-page-title-main">Clozapine</span> Atypical antipsychotic medication

Clozapine is a psychiatric medication and is the first atypical antipsychotic to be discovered. It is primarily used to treat people with schizophrenia and schizoaffective disorder who have had an inadequate response to two other antipsychotics or who have been unable to tolerate other drugs due to extrapyramidal side effects. It is also used for the treatment of psychosis in Parkinson's disease.

<span class="mw-page-title-main">Atypical antipsychotic</span> Class of pharmaceutical drugs

The atypical antipsychotics (AAP), also known as second generation antipsychotics (SGAs) and serotonin–dopamine antagonists (SDAs), are a group of antipsychotic drugs largely introduced after the 1970s and used to treat psychiatric conditions. Some atypical antipsychotics have received regulatory approval for schizophrenia, bipolar disorder, irritability in autism, and as an adjunct in major depressive disorder.

<span class="mw-page-title-main">Risperidone</span> Antipsychotic medication

Risperidone, sold under the brand name Risperdal among others, is an atypical antipsychotic used to treat schizophrenia and bipolar disorder. It is taken either by mouth or by injection. The injectable versions are long-acting and last for 2–4 weeks.

<span class="mw-page-title-main">Quetiapine</span> Atypical antipsychotic medication

Quetiapine, sold under the brand name Seroquel among others, is an atypical antipsychotic medication used for the treatment of schizophrenia, bipolar disorder, and major depressive disorder. Despite being widely used as a sleep aid due to its sedating effect, the benefits of such use may not outweigh its undesirable side effects. It is taken orally.

<span class="mw-page-title-main">Ziprasidone</span> Antipsychotic medication

Ziprasidone, sold under the brand name Geodon among others, is an atypical antipsychotic used to treat schizophrenia and bipolar disorder. It may be used by mouth and by injection into a muscle (IM). The IM form may be used for acute agitation in people with schizophrenia.

<span class="mw-page-title-main">Olanzapine</span> Atypical antipsychotic medication

Olanzapine, sold under the brand name Zyprexa among others, is an atypical antipsychotic primarily used to treat schizophrenia and bipolar disorder. For schizophrenia, it can be used for both new-onset disease and long-term maintenance. It is taken by mouth or by injection into a muscle.

<span class="mw-page-title-main">Aripiprazole</span> Atypical antipsychotic

Aripiprazole, sold under the brand names Abilify and Aristada, among others, is an atypical antipsychotic. It is primarily used in the treatment of schizophrenia and bipolar disorder; other uses include as an add-on treatment in major depressive disorder and obsessive compulsive disorder (OCD), tic disorders, and irritability associated with autism. Aripiprazole is taken by mouth or via injection into a muscle. A Cochrane review found low-quality evidence of effectiveness in treating schizophrenia.

<span class="mw-page-title-main">Loxapine</span> Antipsychotic medication

Loxapine, sold under the brand names Loxitane and Adasuve among others, is a tricyclic antipsychotic medication used primarily in the treatment of schizophrenia. The medicine is a member of the dibenzoxazepine class and structurally very similar to clozapine. Several researchers have argued that loxapine, initially classified as a typical antipsychotic, behaves as an atypical antipsychotic.

The dopamine hypothesis of schizophrenia or the dopamine hypothesis of psychosis is a model that attributes the positive symptoms of schizophrenia to a disturbed and hyperactive dopaminergic signal transduction. The model draws evidence from the observation that a large number of antipsychotics have dopamine-receptor antagonistic effects. The theory, however, does not posit dopamine overabundance as a complete explanation for schizophrenia. Rather, the overactivation of D2 receptors, specifically, is one effect of the global chemical synaptic dysregulation observed in this disorder.

<span class="mw-page-title-main">Dopamine antagonist</span> Drug which blocks dopamine receptors

A dopamine antagonist, also known as an anti-dopaminergic and a dopamine receptor antagonist (DRA), is a type of drug which blocks dopamine receptors by receptor antagonism. Most antipsychotics are dopamine antagonists, and as such they have found use in treating schizophrenia, bipolar disorder, and stimulant psychosis. Several other dopamine antagonists are antiemetics used in the treatment of nausea and vomiting.

<span class="mw-page-title-main">Amisulpride</span> Atypical antipsychotic and antiemetic medication

Amisulpride is an antiemetic and antipsychotic medication used at lower doses intravenously to prevent and treat postoperative nausea and vomiting; and at higher doses by mouth to treat schizophrenia and acute psychotic episodes. It is sold under the brand names Barhemsys and Solian, Socian, Deniban and others. At very low doses it is also used to treat dysthymia.

<span class="mw-page-title-main">Zotepine</span> Atypical antipsychotic medication

Zotepine is an atypical antipsychotic drug indicated for acute and chronic schizophrenia. It has been used in Germany since 1990 and Japan since 1982.

The emphasis of the treatment of bipolar disorder is on effective management of the long-term course of the illness, which can involve treatment of emergent symptoms. Treatment methods include pharmacological and psychological techniques.

Extrapyramidal symptoms (EPS) are symptoms that are archetypically associated with the extrapyramidal system of the brain's cerebral cortex. When such symptoms are caused by medications or other drugs, they are also known as extrapyramidal side effects (EPSE). The symptoms can be acute (short-term) or chronic (long-term). They include movement dysfunction such as dystonia, akathisia, parkinsonism characteristic symptoms such as rigidity, bradykinesia, tremor, and tardive dyskinesia. Extrapyramidal symptoms are a reason why subjects drop out of clinical trials of antipsychotics; of the 213 (14.6%) subjects that dropped out of one of the largest clinical trials of antipsychotics, 58 (27.2%) of those discontinuations were due to EPS.

<span class="mw-page-title-main">Asenapine</span> Medication to treat schizophrenia

Asenapine, sold under the brand name Saphris among others, is an atypical antipsychotic medication used to treat schizophrenia and acute mania associated with bipolar disorder as well as the medium to long-term management of bipolar disorder.

The management of schizophrenia usually involves many aspects including psychological, pharmacological, social, educational, and employment-related interventions directed to recovery, and reducing the impact of schizophrenia on quality of life, social functioning, and longevity.

<span class="mw-page-title-main">Lurasidone</span> Atypical antipsychotic medication

Lurasidone, sold under the brand name Latuda among others, is an antipsychotic medication used to treat schizophrenia and bipolar disorder. It is taken by mouth.

<span class="mw-page-title-main">Antipsychotic switching</span> Process of transferring between antipsychotics

Antipsychotic switching refers to the process of switching out one antipsychotic for another antipsychotic. There are multiple indications for switching antipsychotics, including inadequate efficacy and drug intolerance. There are several strategies that have been theorized for antipsychotic switching, based upon the timing of discontinuation and tapering of the original antipsychotic and the timing of initiation and titration of the new antipsychotic. Major adverse effects from antipsychotic switching may include supersensitivity syndromes, withdrawal, and rebound syndromes.

References

  1. 1 2 Finkel R, Clark MA, Cubeddu LX (2009). Pharmacology. Lippincott Williams & Wilkins. p. 151. ISBN   978-0-7817-7155-9. Archived from the original on 1 April 2017.
  2. ↑ Burnett GB (1975). "The assessment of thiothixene in chronic schizophrenia. A double-blind controlled trial". Dis Nerv Syst. 36 (11): 625–9. PMID   1102277.
  3. 1 2 3 4 5 6 7 8 9 Bartoli F, Cavaleri D, Callovini T, Riboldi I, Crocamo C, D'Agostino A, Martinotti G, Bertolini F, Ostuzzi G, Barbui C, Carrà G (March 2022). "Comparing 1-year effectiveness and acceptability of once-monthly paliperidone palmitate and aripiprazole monohydrate for schizophrenia spectrum disorders: Findings from the STAR Network Depot Study". Psychiatry Research. 309: 114405. doi:10.1016/j.psychres.2022.114405. PMID   35093701. S2CID   246054926.
  4. ↑ Lally J, MacCabe JH (June 2015). "Antipsychotic medication in schizophrenia: a review". British Medical Bulletin. 114 (1): 169–79. doi: 10.1093/bmb/ldv017 . PMID   25957394. Antipsychotic medications are mainstays in the treatment of schizophrenia and a range of other psychotic disorders.
  5. ↑ Grande I, Berk M, Birmaher B, Vieta E (April 2016). "Bipolar disorder". Lancet. 387 (10027): 1561–1572. doi:10.1016/S0140-6736(15)00241-X. PMID   26388529. S2CID   205976059.
  6. 1 2 Ho BC, Andreasen NC, Ziebell S, Pierson R, Magnotta V (February 2011). "Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia". Archives of General Psychiatry. 68 (2): 128–137. doi:10.1001/archgenpsychiatry.2010.199. PMC   3476840 . PMID   21300943.
  7. 1 2 Moncrieff J, Leo J (September 2010). "A systematic review of the effects of antipsychotic drugs on brain volume". Psychological Medicine. 40 (9): 1409–1422. doi:10.1017/S0033291709992297. PMID   20085668. S2CID   23522488.
  8. 1 2 Chopra S, Fornito A, Francey SM, O'Donoghue B, Cropley V, Nelson B, et al. (July 2021). "Differentiating the effect of antipsychotic medication and illness on brain volume reductions in first-episode psychosis: A Longitudinal, Randomised, Triple-blind, Placebo-controlled MRI Study". Neuropsychopharmacology. 46 (8): 1494–1501. doi:10.1038/s41386-021-00980-0. PMC   8209146 . PMID   33637835.
  9. ↑ Lawrie SM, Abukmeil SS (1998). "Brain abnormality in schizophrenia". British Journal of Psychiatry. 172 (2): 110–120. doi:10.1192/bjp.172.2.110. ISSN   0007-1250. PMID   9519062. S2CID   23604963.
  10. ↑ please see Chopra et al 2021: Strengths and limitations "only examined risperidone and paliperidone"
  11. ↑ please see Chopra et al 2021: Method Study design
  12. ↑ please see Chopra et al 2021: Introduction, 3rd paragraph, Lieberman JA, et al. 2005 & Shao Y et al 2015, and Chopra et al: Are antipsychotics neuroprotective? 1st paragraph last sentence
  13. ↑ Shen WW (December 1999). "A history of antipsychotic drug development". Comprehensive Psychiatry. 40 (6): 407–14. doi:10.1016/s0010-440x(99)90082-2. PMID   10579370.
  14. ↑ Aringhieri S, Carli M, Kolachalam S, Verdesca V, Cini E, Rossi M, et al. (December 2018). "Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences". Pharmacology & Therapeutics. 192: 20–41. doi:10.1016/j.pharmthera.2018.06.012. PMID   29953902. S2CID   49602956.
  15. 1 2 Mailman RB, Murthy V (2010). "Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?". Current Pharmaceutical Design. 16 (5): 488–501. doi:10.2174/138161210790361461. PMC   2958217 . PMID   19909227.
  16. 1 2 3 4 5 6 7 8 King C, Voruganti LN (May 2002). "What's in a name? The evolution of the nomenclature of antipsychotic drugs". Journal of Psychiatry & Neuroscience. 27 (3): 168–175. PMC   161646 . PMID   12066446.
  17. 1 2 3 4 5 Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (January 2009). "Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis". Lancet. 373 (9657): 31–41. doi:10.1016/S0140-6736(08)61764-X. PMID   19058842. S2CID   1071537.
  18. ↑ Goikolea JM, Colom F, Torres I, Capapey J, Valentí M, Undurraga J, Grande I, Sanchez-Moreno J, Vieta E (January 2013). "Lower rate of depressive switch following antimanic treatment with second-generation antipsychotics versus haloperidol". Journal of Affective Disorders. 144 (3): 191–8. doi:10.1016/j.jad.2012.07.038. PMID   23089129.
  19. 1 2 3 4 5 6 Taylor D, Paton C, Kapur S, Taylor D (2012). The Maudsley prescribing guidelines in psychiatry (11th ed.). Chichester, West Sussex, UK: Wiley-Blackwell. ISBN   978-0-470-97948-8.
  20. 1 2 3 "American Psychiatric Association Five Things Physicians and Patients Should Question". Choosing Wisely. Archived from the original on 3 December 2013. Retrieved 23 September 2013.
  21. ↑ Budman CL (July 2014). "The role of atypical antipsychotics for treatment of Tourette's syndrome: an overview". Drugs. 74 (11): 1177–1193. doi:10.1007/s40265-014-0254-0. PMID   25034359. S2CID   24378317.
  22. ↑ Basson R, Gilks T (1 January 2018). "Women's sexual dysfunction associated with psychiatric disorders and their treatment". Women's Health. 14: 1745506518762664. doi:10.1177/1745506518762664. PMC   5900810 . PMID   29649948.
  23. ↑ Kreys TJ, Phan SV (February 2015). "A literature review of quetiapine for generalized anxiety disorder". Pharmacotherapy. 35 (2): 175–188. doi:10.1002/phar.1529. PMID   25689246. S2CID   24744675.
  24. 1 2 3 4 "Psychosis and schizophrenia in adults (CG178)". 12 February 2014. Archived from the original on 4 March 2014.
  25. ↑ "American Psychiatric Association Practice Guidelines". Psychiatry Online.
  26. 1 2 3 4 5 6 7 Barnes TR (May 2011). "Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology". Journal of Psychopharmacology. 25 (5): 567–620. doi:10.1177/0269881110391123. PMID   21292923. S2CID   40089561.
  27. ↑ Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA (December 2012). "Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents". Molecular Psychiatry. 17 (12): 1206–27. doi: 10.1038/mp.2012.47 . PMID   22584864.
  28. 1 2 Hartling L, Abou-Setta AM, Dursun S, Mousavi SS, Pasichnyk D, Newton AS (October 2012). "Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications: a systematic review and meta-analysis". Annals of Internal Medicine. 157 (7): 498–511. doi: 10.7326/0003-4819-157-7-201210020-00525 . PMID   22893011.
  29. ↑ Furukawa TA, Levine SZ, Tanaka S, Goldberg Y, Samara M, Davis JM, Cipriani A, Leucht S (January 2015). "Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies". JAMA Psychiatry. 72 (1): 14–21. doi: 10.1001/jamapsychiatry.2014.2127 . PMID   25372935.
  30. ↑ Keefe RS, Silva SG, Perkins DO, Lieberman JA (1 January 1999). "The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis". Schizophrenia Bulletin. 25 (2): 201–22. doi: 10.1093/oxfordjournals.schbul.a033374 . PMID   10416727.
  31. ↑ "NICE Treatment Guidance 2014". Archived from the original on 13 August 2014. Retrieved 7 August 2014.
  32. ↑ McGorry PD, Hartmann JA, Spooner R, Nelson B (June 2018). "Beyond the "at risk mental state" concept: transitioning to transdiagnostic psychiatry". World Psychiatry. 17 (2): 133–142. doi:10.1002/wps.20514. PMC   5980504 . PMID   29856558.
  33. 1 2 Starzer MS, Nordentoft M, Hjorthøj C (April 2018). "Rates and Predictors of Conversion to Schizophrenia or Bipolar Disorder Following Substance-Induced Psychosis". The American Journal of Psychiatry. 175 (4). American Psychiatric Association Publishing: 343–350. doi: 10.1176/appi.ajp.2017.17020223 . PMID   29179576.
  34. ↑ Robinson DG, Gallego JA, John M, Petrides G, Hassoun Y, Zhang JP, et al. (November 2015). "A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes". Schizophrenia Bulletin. 41 (6): 1227–1236. doi:10.1093/schbul/sbv125. PMC   4601722 . PMID   26338693.
  35. ↑ Gómez-Revuelta M, Pelayo-Terán JM, Juncal-Ruiz M, Vázquez-Bourgon J, Suárez-Pinilla P, Romero-Jiménez R, et al. (April 2020). "Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone". The International Journal of Neuropsychopharmacology. 23 (4): 217–229. doi:10.1093/ijnp/pyaa004. PMC   7177160 . PMID   31974576.
  36. ↑ Leucht S, Arbter D, Engel RR, Kissling W, Davis JM (April 2009). "How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials". Molecular Psychiatry. 14 (4): 429–47. doi: 10.1038/sj.mp.4002136 . PMID   18180760.
  37. 1 2 3 4 5 6 7 8 9 Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti G, Davis JM (September 2013). "Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis". Lancet. 382 (9896): 951–62. doi:10.1016/S0140-6736(13)60733-3. PMID   23810019. S2CID   32085212.
  38. ↑ Beitinger R, Lin J, Kissling W, Leucht S (October 2008). "Comparative remission rates of schizophrenic patients using various remission criteria". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 32 (7): 1643–51. doi:10.1016/j.pnpbp.2008.06.008. PMID   18616969. S2CID   207408308.
  39. 1 2 Ceraso A, Lin JJ, Schneider-Thoma J, Siafis S, Tardy M, Komossa K, et al. (August 2020). "Maintenance treatment with antipsychotic drugs for schizophrenia". The Cochrane Database of Systematic Reviews. 2020 (8): CD008016. doi:10.1002/14651858.CD008016.pub3. PMC   9702459 . PMID   32840872. S2CID   221306099.
  40. 1 2 Tiihonen J, Tanskanen A, Taipale H (August 2018). "20-Year Nationwide Follow-Up Study on Discontinuation of Antipsychotic Treatment in First-Episode Schizophrenia". The American Journal of Psychiatry. 175 (8). American Psychiatric Association Publishing: 765–773. doi: 10.1176/appi.ajp.2018.17091001 . PMID   29621900.
  41. ↑ Kinon BJ, Ascher-Svanum H, Adams DH, Chen L (October 2008). "The temporal relationship between symptom change and treatment discontinuation in a pooled analysis of 4 schizophrenia trials". Journal of Clinical Psychopharmacology. 28 (5): 544–9. doi:10.1097/JCP.0b013e318185e74a. PMID   18794651. S2CID   203910.
  42. 1 2 Park SC, Choi MY, Choi J, Park E, Tchoe HJ, Suh JK, et al. (November 2018). "Comparative Efficacy and Safety of Long-acting Injectable and Oral Second-generation Antipsychotics for the Treatment of Schizophrenia: A Systematic Review and Meta-analysis". Clinical Psychopharmacology and Neuroscience. 16 (4): 361–375. doi:10.9758/cpn.2018.16.4.361. PMC   6245299 . PMID   30466208.
  43. ↑ "PSYCHOSIS and Schizophreniain adults: THE NICE GUIDELINE ON TREATMENT AND MANAGEMENT". p. 10.11.1.27.
  44. ↑ Lambert TJ, Singh BS, Patel MX (November 2009). "Community treatment orders and antipsychotic long-acting injections". The British Journal of Psychiatry. Supplement. 52 (S52). Royal College of Psychiatrists: S57-62. doi: 10.1192/bjp.195.52.s57 . PMID   19880919.
  45. 1 2 Young LL, Kradjan WA, Guglielmo BJ, Corelli RL, Williams BR, Koda-Kimble MA (2009). Applied therapeutics: the clinical use of drugs (9th ed.). Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. p. 3040. ISBN   978-0-7817-6555-8.
  46. ↑ Correll CU, Sheridan EM, DelBello MP (March 2010). "Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials". Bipolar Disorders. 12 (2): 116–41. doi:10.1111/j.1399-5618.2010.00798.x. PMID   20402706.
  47. ↑ "DailyMed - CAPLYTA- lumateperone capsule". dailymed.nlm.nih.gov. Retrieved 10 December 2022.
  48. ↑ Earley W, Burgess MV, Rekeda L, Dickinson R, Szatmári B, Németh G, et al. (June 2019). "Cariprazine Treatment of Bipolar Depression: A Randomized Double-Blind Placebo-Controlled Phase 3 Study". The American Journal of Psychiatry. 176 (6): 439–448. doi: 10.1176/appi.ajp.2018.18070824 . PMID   30845817. S2CID   73471270.
  49. ↑ Lowes R. "Lurasidone Approved for Bipolar Depression". Medscape. Archived from the original on 2 October 2013. Retrieved 2 October 2013.
  50. ↑ Tohen M, Katagiri H, Fujikoshi S, Kanba S (July 2013). "Efficacy of olanzapine monotherapy in acute bipolar depression: a pooled analysis of controlled studies". Journal of Affective Disorders. 149 (1–3): 196–201. doi:10.1016/j.jad.2013.01.022. PMID   23485111.
  51. ↑ Thase ME (February 2008). "Quetiapine monotherapy for bipolar depression". Neuropsychiatric Disease and Treatment. 4 (1): 11–21. doi: 10.2147/ndt.s1162 . PMC   2515925 . PMID   18728771.
  52. ↑ Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, et al. (July 2005). "Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial". The American Journal of Psychiatry. 162 (7): 1281–1290. doi:10.1176/appi.ajp.162.7.1281. PMID   15994710. S2CID   20932562.
  53. ↑ Duffy A, Milin R, Grof P (February 2009). "Maintenance treatment of adolescent bipolar disorder: open study of the effectiveness and tolerability of quetiapine". BMC Psychiatry. 9: 4. doi: 10.1186/1471-244X-9-4 . PMC   2644292 . PMID   19200370.
  54. ↑ Weisler RH, Nolen WA, Neijber A, Hellqvist A, Paulsson B (November 2011). "Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study)". The Journal of Clinical Psychiatry. 72 (11): 1452–1464. doi:10.4088/JCP.11m06878. PMID   22054050.
  55. ↑ Cipriani A, Rendell JM, Geddes J (January 2009). Cipriani A (ed.). "Olanzapine in long-term treatment for bipolar disorder". The Cochrane Database of Systematic Reviews (1): CD004367. doi:10.1002/14651858.CD004367.pub2. PMID   19160237. S2CID   205173641.
  56. ↑ Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J (February 2004). "Practice guideline for the treatment of patients with schizophrenia, second edition". The American Journal of Psychiatry. 161 (2 Suppl): 1–56. PMID   15000267.
  57. ↑ National Collaborating Centre (2009). "Schizophrenia". NCBI Bookshelf. PMID   20704054 . Retrieved 9 March 2021.
  58. 1 2 3 4 Ventimiglia J, Kalali AH, Vahia IV, Jeste DV (November 2010). "An analysis of the intended use of atypical antipsychotics in dementia". Psychiatry. 7 (11): 14–17. PMC   3010964 . PMID   21191528.
  59. ↑ AMDA – The Society for Post-Acute and Long-Term Care Medicine (February 2014). "Ten Things Physicians and Patients Should Question". Choosing Wisely: an initiative of the ABIM Foundation . AMDA – The Society for Post-Acute and Long-Term Care Medicine. Archived from the original on 13 September 2014. Retrieved 20 April 2015..
  60. ↑ Ballard C, Waite J (January 2006). Ballard CG (ed.). "The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease". The Cochrane Database of Systematic Reviews (1): CD003476. doi:10.1002/14651858.CD003476.pub2. PMID   16437455.
  61. ↑ Lühnen J, Richter T, Calo S, Meyer G, Köpke S, Möhler R (August 2023). "Psychosocial interventions for reducing antipsychotic medication in care home residents". The Cochrane Database of Systematic Reviews. 2023 (8): CD008634. doi:10.1002/14651858.CD008634.pub3. PMC  10471006. PMID   37650479.
  62. 1 2 Komossa K, Depping AM, Gaudchau A, Kissling W, Leucht S (December 2010). "Second-generation antipsychotics for major depressive disorder and dysthymia". The Cochrane Database of Systematic Reviews (12): CD008121. doi:10.1002/14651858.CD008121.pub2. PMID   21154393.
  63. ↑ Spielmans GI, Berman MI, Linardatos E, Rosenlicht NZ, Perry A, Tsai AC (2013). "Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes". PLOS Medicine. 10 (3): e1001403. doi: 10.1371/journal.pmed.1001403 . PMC   3595214 . PMID   23554581.
  64. ↑ Truven Health Analytics, Inc. DrugPoint System (Internet) [cited 2013 Oct 2]. Greenwood Village, CO: Thomsen Healthcare; 2013.
  65. ↑ "FDA Psychopharmacologic Drugs Advisory Committee Hearing" (PDF). American Academy of Child & Adolescent Psychiatry. Archived (PDF) from the original on 9 October 2022. Retrieved 31 May 2020.
  66. ↑ Al-Wandi A, Landén M, Nordenskjöld A (6 November 2023). "Antipsychotics in the maintenance phase for psychotic depression". Acta Psychiatrica Scandinavica. 149 (1): 6–17. doi: 10.1111/acps.13628 . ISSN   0001-690X. PMID   37932158.
  67. ↑ Hálfdánarson Ó, Zoëga H, Aagaard L, Bernardo M, Brandt L, Fusté AC, Furu K, Garuoliené K, Hoffmann F, Huybrechts KF, Kalverdijk LJ, Kawakami K, Kieler H, Kinoshita T, Litchfield M (October 2017). "International trends in antipsychotic use: A study in 16 countries, 2005-2014". European Neuropsychopharmacology. 27 (10): 1064–1076. doi:10.1016/j.euroneuro.2017.07.001. ISSN   1873-7862. PMID   28755801.
  68. ↑ Radha Krishnan RP, Harrison C, Buckley N, Raubenheimer JE (April 2024). "On- and off-label utilisation of antipsychotics in Australia (2000–2021): Retrospective analysis of two medication datasets". Australian & New Zealand Journal of Psychiatry. 58 (4): 320–333. doi: 10.1177/00048674231210209 . ISSN   0004-8674. PMC   10960313 . PMID   37941354.
  69. ↑ McKean A, Monasterio E (1 May 2012). "Off-label use of atypical antipsychotics: cause for concern?". CNS Drugs. 26 (5): 383–390. doi:10.2165/11632030-000000000-00000. ISSN   1179-1934. PMID   22448598.
  70. 1 2 Maher AR, Theodore G (June 2012). "Summary of the comparative effectiveness review on off-label use of atypical antipsychotics". Journal of Managed Care Pharmacy. 18 (5 Suppl B): S1-20. doi: 10.18553/jmcp.2012.18.s5-b.1 . PMC   10438344 . PMID   22784311.
  71. 1 2 Maglione M, Maher AR, Hu J, Wang Z, Shanman R, Shekelle PG, Roth B, Hilton L, Suttorp MJ (2011). Off-Label Use of Atypical Antipsychotics: An Update. Comparative Effectiveness Reviews, No. 43. Rockville: Agency for Healthcare Research and Quality. PMID   22973576.
  72. ↑ Coe HV, Hong IS (May 2012). "Safety of low doses of quetiapine when used for insomnia". The Annals of Pharmacotherapy. 46 (5): 718–722. doi:10.1345/aph.1Q697. PMID   22510671. S2CID   9888209.
  73. ↑ Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, et al. (January 2020). "Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis". The Lancet. Psychiatry. 7 (1): 64–77. doi:10.1016/s2215-0366(19)30416-x. PMC   7029416 . PMID   31860457.
  74. ↑ Yoshida K, Takeuchi H (March 2021). "Dose-dependent effects of antipsychotics on efficacy and adverse effects in schizophrenia". Behavioural Brain Research. 402: 113098. doi: 10.1016/j.bbr.2020.113098 . PMID   33417992. S2CID   230507941.
  75. ↑ De Crescenzo F, D'Alò GL, Ostinelli EG, Ciabattini M, Di Franco V, Watanabe N, et al. (July 2022). "Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis". Lancet. 400 (10347): 170–184. doi: 10.1016/S0140-6736(22)00878-9 . hdl: 11380/1288245 . PMID   35843245. S2CID   250536370.
  76. ↑ Work Group on Borderline Personality Disorder (2001). Practice Guideline for the Treatment of Patients With Borderline Personality Disorder. American Psychiatric Association Publications. p. 4. ISBN   978-0-89042-319-6 . Retrieved 5 June 2013.
  77. ↑ "Antipsychotics are commonly prescribed to people with personality disorders, contrary to guidelines". NIHR Evidence. 10 November 2022. doi:10.3310/nihrevidence_54520. S2CID   253467990.
  78. ↑ Hardoon S, Hayes J, Viding E, McCrory E, Walters K, Osborn D (March 2022). "Prescribing of antipsychotics among people with recorded personality disorder in primary care: a retrospective nationwide cohort study using The Health Improvement Network primary care database". BMJ Open. 12 (3): e053943. doi:10.1136/bmjopen-2021-053943. PMC   8968526 . PMID   35264346.
  79. ↑ Zuddas A, Zanni R, Usala T (August 2011). "Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies". European Neuropsychopharmacology. 21 (8): 600–20. doi:10.1016/j.euroneuro.2011.04.001. PMID   21550212. S2CID   1254352.
  80. ↑ Pringsheim T, Doja A, Gorman D, McKinlay D, Day L, Billinghurst L, Carroll A, Dion Y, Luscombe S, Steeves T, Sandor P (March 2012). "Canadian guidelines for the evidence-based treatment of tic disorders: pharmacotherapy". Canadian Journal of Psychiatry. 57 (3): 133–43. doi: 10.1177/070674371205700302 . PMID   22397999.
  81. ↑ McPheeters ML, Warren Z, Sathe N, Bruzek JL, Krishnaswami S, Jerome RN, Veenstra-Vanderweele J (May 2011). "A systematic review of medical treatments for children with autism spectrum disorders". Pediatrics. 127 (5): e1312–21. doi:10.1542/peds.2011-0427. PMID   21464191. S2CID   2903864.
  82. ↑ "Evidence Lacking to Support Many Off-label Uses of Atypical Antipsychotics" (Press release). Agency for Healthcare Research and Quality. 17 January 2007. Archived from the original on 25 February 2013. Retrieved 29 July 2013.
  83. ↑ James AC (2010). "Prescribing antipsychotics for children and adolescents". Advances in Psychiatric Treatment. 16 (1): 63–75. doi: 10.1192/apt.bp.108.005652 .
  84. ↑ Truven Health Analytics, Inc. DRUGDEX System (Internet) [cited 2013 Oct 10]. Greenwood Village, CO: Thomsen Healthcare; 2013.
  85. ↑ "Antipsychotics are increasingly prescribed to children and teenagers". NIHR Evidence. 18 April 2023. doi:10.3310/nihrevidence_57289. S2CID   258224542.
  86. ↑ Radojčić MR, Pierce M, Hope H, Senior M, Taxiarchi VP, Trefan L, et al. (February 2023). "Trends in antipsychotic prescribing to children and adolescents in England: cohort study using 2000-19 primary care data". The Lancet. Psychiatry. 10 (2): 119–128. doi: 10.1016/s2215-0366(22)00404-7 . PMID   36638816. S2CID   255703855.
  87. ↑ Romeo R, Knapp M, Tyrer P, Crawford M, Oliver-Africano P (July 2009). "The treatment of challenging behaviour in intellectual disabilities: cost-effectiveness analysis". Journal of Intellectual Disability Research. 53 (7): 633–43. doi:10.1111/j.1365-2788.2009.01180.x. PMID   19460067. S2CID   34448894.
  88. ↑ Linton D, Barr AM, Honer WG, Procyshyn RM (May 2013). "Antipsychotic and psychostimulant drug combination therapy in attention deficit/hyperactivity and disruptive behavior disorders: a systematic review of efficacy and tolerability". Current Psychiatry Reports. 15 (5): 355. doi:10.1007/s11920-013-0355-6. PMID   23539465. S2CID   45484062.
  89. ↑ Oh ES, Needham DM, Nikooie R, Wilson LM, Zhang A, Robinson KA, Neufeld KJ (October 2019). "Antipsychotics for Preventing Delirium in Hospitalized Adults: A Systematic Review". Annals of Internal Medicine. 171 (7): 474–484. doi: 10.7326/M19-1859 . PMID   31476766.
  90. ↑ Kane JM, Correll CU (2010). "Pharmacologic treatment of schizophrenia". Dialogues in Clinical Neuroscience. 12 (3): 345–57. doi:10.31887/DCNS.2010.12.3/jkane. PMC   3085113 . PMID   20954430.
  91. ↑ Barry SJ, Gaughan TM, Hunter R (June 2012). "Schizophrenia". BMJ Clinical Evidence. 2012. PMC   3385413 . PMID   23870705.
  92. ↑ Schultz SH, North SW, Shields CG (June 2007). "Schizophrenia: a review". American Family Physician. 75 (12): 1821–9. CiteSeerX   10.1.1.602.7571 . PMID   17619525.
  93. ↑ Taylor DM, Duncan-McConnell D (2000). "Refractory schizophrenia and atypical antipsychotics". Journal of Psychopharmacology. 14 (4): 409–18. doi:10.1177/026988110001400411. PMID   11198061. S2CID   27270415.
  94. ↑ Essali A, Al-Haj Haasan N, Li C, Rathbone J (January 2009). "Clozapine versus typical neuroleptic medication for schizophrenia". The Cochrane Database of Systematic Reviews. 2009 (1): CD000059. doi:10.1002/14651858.CD000059.pub2. PMC   7065592 . PMID   19160174.
  95. ↑ Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S (February 2006). "Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics". The American Journal of Psychiatry. 163 (2): 185–94. doi:10.1176/appi.ajp.163.2.185. PMID   16449469. S2CID   3849348.
  96. ↑ Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK (September 2005). "Effectiveness of antipsychotic drugs in patients with chronic schizophrenia". The New England Journal of Medicine. 353 (12): 1209–23. doi: 10.1056/NEJMoa051688 . PMID   16172203. S2CID   22499842.
  97. ↑ Swartz MS, Stroup TS, McEvoy JP, Davis SM, Rosenheck RA, Keefe RS, Hsiao JK, Lieberman JA (May 2008). "Special Section on Implications of CATIE: What CATIE Found: Results From the Schizophrenia Trial". Psychiatric Services. 59 (5): 500–506. doi:10.1176/ps.2008.59.5.500. ISSN   1075-2730. PMC   5033643 . PMID   18451005.
  98. ↑ Voruganti LP, Baker LK, Awad AG (March 2008). "New generation antipsychotic drugs and compliance behaviour". Current Opinion in Psychiatry. 21 (2): 133–9. doi:10.1097/YCO.0b013e3282f52851. PMID   18332660. S2CID   34935.
  99. ↑ Paczynski RP, Alexander GC, Chinchilli VM, Kruszewski SP (January 2012). "Quality of evidence in drug compendia supporting off-label use of typical and atypical antipsychotic medications". The International Journal of Risk & Safety in Medicine. 24 (3): 137–146. doi:10.3233/JRS-2012-0567. PMID   22936056.
  100. ↑ Owens DC (2008). "How CATIE brought us back to Kansas: a critical re-evaluation of the concept of atypical antipsychotics and their place in the treatment of schizophrenia". Advances in Psychiatric Treatment. 14 (1): 17–28. doi: 10.1192/apt.bp.107.003970 .
  101. ↑ Fischer-Barnicol D, Lanquillon S, Haen E, Zofel P, Koch HJ, Dose M, Klein HE (2008). "Typical and atypical antipsychotics--the misleading dichotomy. Results from the Working Group 'Drugs in Psychiatry' (AGATE)". Neuropsychobiology. 57 (1–2): 80–87. doi:10.1159/000135641. PMID   18515977. S2CID   2669203.
  102. ↑ Casey DE (March 1999). "Tardive dyskinesia and atypical antipsychotic drugs". Schizophrenia Research. 35 (Suppl 1): S61–S66. doi:10.1016/S0920-9964(98)00160-1. PMID   10190226. S2CID   31807817.
  103. ↑ Makhinson M (January 2010). "Biases in medication prescribing: the case of second-generation antipsychotics". Journal of Psychiatric Practice. 16 (1): 15–21. doi:10.1097/01.pra.0000367774.11260.e4. PMID   20098227. S2CID   46530288.
  104. 1 2 3 American Psychiatric Association (September 2013). "Five Things Physicians and Patients Should Question". Choosing Wisely: an initiative of the ABIM Foundation . American Psychiatric Association. Archived from the original on 3 December 2013. Retrieved 30 December 2013., which cites
  105. 1 2 Barry SJ, Gaughan TM, Hunter R (June 2012). "Schizophrenia". BMJ Clin Evid. 2012. PMC   3385413 . PMID   23870705.
  106. ↑ Nakata Y, Kanahara N, Iyo M (December 2017). "Dopamine supersensitivity psychosis in schizophrenia: Concepts and implications in clinical practice". Journal of Psychopharmacology. 31 (12): 1511–1518. doi:10.1177/0269881117728428. PMID   28925317. S2CID   1957881.
  107. ↑ Ware MR, Feller DB, Hall KL (4 January 2018). "Neuroleptic Malignant Syndrome: Diagnosis and Management". The Primary Care Companion for CNS Disorders. 20 (1). doi:10.4088/PCC.17r02185. PMID   29325237.
  108. ↑ Carbon M, Kane JM, Leucht S, Correll CU (October 2018). "Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis". World Psychiatry. 17 (3): 330–340. doi:10.1002/wps.20579. PMC   6127753 . PMID   30192088.
  109. ↑ Moore DP, Puri BK (2012). Textbook of Clinical Neuropsychiatry and Behavioral Neuroscience, Third Edition. CRC Press. p. 791. ISBN   978-1-4441-6494-7. Archived from the original on 25 November 2017.
  110. 1 2 De Berardis D, Rapini G, Olivieri L, et al. (May 2018). "Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine". Therapeutic Advances in Drug Safety. 9 (5): 237–256. doi:10.1177/2042098618756261. PMC   5956953 . PMID   29796248.
  111. ↑ Legge SE, Walters JT (March 2019). "Genetics of clozapine-associated neutropenia: recent advances, challenges and future perspective". Pharmacogenomics. 20 (4): 279–290. doi:10.2217/pgs-2018-0188. PMC   6563116 . PMID   30767710.
  112. ↑ Kritharides L, Chow V, Lambert TJ (6 February 2017). "Cardiovascular disease in patients with schizophrenia". The Medical Journal of Australia. 206 (2): 91–95. doi:10.5694/mja16.00650. PMID   28152356. S2CID   5388097.
  113. 1 2 Sarvaiya N, Lapitskaya Y, Dima L, Manu P (August 2018). "Clozapine-Associated Pulmonary Embolism: A High-Mortality, Dose-Independent and Early-Onset Adverse Effect". American Journal of Therapeutics. 25 (4): e434–e438. doi:10.1097/MJT.0000000000000806. PMID   29985823. S2CID   51608744.
  114. ↑ Teodoro T, Nogueira V, Aldeias J, Teles Martins M, Salgado J (September 2022). "Clozapine Associated Periorbital Edema in First Episode Psychosis: A Case Report of a Rare Adverse Effect in Treatment-Resistant Schizophrenia". Journal of Clinical Psychopharmacology. 42 (6): 594–596. doi:10.1097/JCP.0000000000001600. PMID   36066404. S2CID   252088054.
  115. ↑ Citrome L, McEvoy JP, Saklad SR (2016). "Guide to the Management of Clozapine-Related Tolerability and Safety Concerns". Clinical Schizophrenia & Related Psychoses. 10 (3): 163–177. doi:10.3371/1935-1232.10.3.163. PMID   27732102.
  116. ↑ Sriretnakumar V, Huang E, Müller DJ (2015). "Pharmacogenetics of clozapine treatment response and side-effects in schizophrenia: an update". Expert Opinion on Drug Metabolism & Toxicology. 11 (11): 1709–31. doi:10.1517/17425255.2015.1075003. PMID   26364648. S2CID   207492339.
  117. ↑ Picchioni MM, Murray RM (July 2007). "Schizophrenia". BMJ. 335 (7610): 91–5. doi:10.1136/bmj.39227.616447.BE. PMC   1914490 . PMID   17626963.
  118. ↑ Adam RL, Sidi H, Midin M, et al. (2018). "The Role of Atypical Antipsychotics in Sexuality: Road to Recovery in Schizophrenia". Current Drug Targets. 19 (12): 1402–1411. doi:10.2174/1389450118666170502130126. PMID   28464773. S2CID   41487184.
  119. ↑ Muench J, Hamer AM (March 2010). "Adverse effects of antipsychotic medications". American Family Physician. 81 (5): 617–22. PMID   20187598.
  120. ↑ Lieberman JA (2004). "Managing anticholinergic side effects". Primary Care Companion to the Journal of Clinical Psychiatry. 6 (Suppl 2): 20–3. PMC   487008 . PMID   16001097.
  121. ↑ University of Hong Kong (6 September 2022). "Antipsychotic Use Associated With Elevated Risk of Breast Cancer".
  122. ↑ Koller EA, Doraiswamy PM (July 2002). "Olanzapine-associated diabetes mellitus". Pharmacotherapy. 22 (7): 841–52. doi:10.1592/phco.22.11.841.33629. PMID   12126218. S2CID   27314943.
  123. ↑ Weston-Green K, Huang XF, Deng C (February 2010). "Sensitivity of the female rat to olanzapine-induced weight gain—far from the clinic?". Schizophrenia Research. 116 (2–3): 299–300. doi:10.1016/j.schres.2009.09.034. PMID   19840894. S2CID   30384727.
  124. 1 2 3 Brunton LL, Chabner B, Knollmann BC, eds. (2011). Goodman & Gilman's The Pharmacological Basis of Therapeutics (12th ed.). New York: McGraw-Hill. ISBN   978-0-07-162442-8.
  125. ↑ Weston-Green K, Huang XF, Deng C (2012). Chang AY (ed.). "Alterations to melanocortinergic, GABAergic and cannabinoid neurotransmission associated with olanzapine-induced weight gain". PLOS ONE. 7 (3): e33548. Bibcode:2012PLoSO...733548W. doi: 10.1371/journal.pone.0033548 . PMC   3306411 . PMID   22438946.
  126. ↑ Koller EA, Cross JT, Doraiswamy PM, Malozowski SN (September 2003). "Pancreatitis associated with atypical antipsychotics: from the Food and Drug Administration's MedWatch surveillance system and published reports". Pharmacotherapy. 23 (9): 1123–30. doi:10.1592/phco.23.10.1123.32759. PMID   14524644. S2CID   39945446.
  127. ↑ Weinmann S, Read J, Aderhold V (August 2009). "Influence of antipsychotics on mortality in schizophrenia: systematic review". Schizophrenia Research. 113 (1): 1–11. doi:10.1016/j.schres.2009.05.018. PMID   19524406. S2CID   8143217.
  128. ↑ Joukamaa M, Heliövaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V (February 2006). "Schizophrenia, neuroleptic medication and mortality". The British Journal of Psychiatry. 188 (2): 122–7. doi: 10.1192/bjp.188.2.122 . PMID   16449697.
  129. ↑ American Geriatrics Society 2012 Beers Criteria Update Expert Panel (April 2012). "American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults". Journal of the American Geriatrics Society. 60 (4): 616–31. doi:10.1111/j.1532-5415.2012.03923.x. PMC   3571677 . PMID   22376048.{{cite journal}}: CS1 maint: numeric names: authors list (link)
  130. ↑ Medford N, Sierra M, Baker D, David A (2005). "Understanding and treating depersonalisation disorder". Advances in Psychiatric Treatment. 11 (2): 92–100. doi: 10.1192/apt.11.2.92 . Archived from the original on 16 July 2011.
  131. ↑ Patrick V, Levin E, Schleifer S (July 2005). "Antipsychotic polypharmacy: is there evidence for its use?". Journal of Psychiatric Practice. 11 (4): 248–57. doi:10.1097/00131746-200507000-00005. PMID   16041235. S2CID   43114395.
  132. ↑ Ito H, Koyama A, Higuchi T (September 2005). "Polypharmacy and excessive dosing: psychiatrists' perceptions of antipsychotic drug prescription". The British Journal of Psychiatry. 187 (3): 243–7. doi: 10.1192/bjp.187.3.243 . PMID   16135861.
  133. ↑ Leung JC, Ng DW, Chu RY, Chan EW, Huang L, Lum DH, et al. (September 2022). "Association of antipsychotic use with breast cancer: a systematic review and meta-analysis of observational studies with over 2 million individuals". Epidemiology and Psychiatric Sciences. 31: e61. doi:10.1017/S2045796022000476. PMC   9483823 . PMID   36059215.
  134. ↑ Vita A, De Peri L, Deste G, Sacchetti E (November 2012). "Progressive loss of cortical gray matter in schizophrenia: a meta-analysis and meta-regression of longitudinal MRI studies". Translational Psychiatry. 2 (11): e190. doi:10.1038/tp.2012.116. PMC   3565772 . PMID   23168990.
  135. ↑ Radua J, Borgwardt S, Crescini A, Mataix-Cols D, Meyer-Lindenberg A, McGuire PK, Fusar-Poli P (November 2012). "Multimodal meta-analysis of structural and functional brain changes in first episode psychosis and the effects of antipsychotic medication". Neuroscience and Biobehavioral Reviews. 36 (10): 2325–33. doi: 10.1016/j.neubiorev.2012.07.012 . PMID   22910680.
  136. ↑ Dorph-Petersen KA, Pierri JN, Perel JM, Sun Z, Sampson AR, Lewis DA (September 2005). "The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys". Neuropsychopharmacology. 30 (9): 1649–1661. doi: 10.1038/sj.npp.1300710 . PMID   15756305. S2CID   205679212.
  137. ↑ Parks J, Radke A, Parker G, Foti ME, Eilers R, Diamond M, et al. (September 2009). "Principles of antipsychotic prescribing for policy makers, circa 2008. Translating knowledge to promote individualized treatment". Schizophrenia Bulletin. 35 (5): 931–936. doi:10.1093/schbul/sbn019. PMC   2728806 . PMID   18385207.
  138. ↑ Hirose S (2003). "The causes of underdiagnosing akathisia". Schizophrenia Bulletin. 29 (3): 547–58. CiteSeerX   10.1.1.618.3326 . doi:10.1093/oxfordjournals.schbul.a007027. PMID   14609248.
  139. ↑ Rehse M, Bartolovic M, Baum K, Richter D, Weisbrod M, Roesch-Ely D (2016). "Influence of Antipsychotic and Anticholinergic Loads on Cognitive Functions in Patients with Schizophrenia". Schizophrenia Research and Treatment. 2016: 8213165. doi: 10.1155/2016/8213165 . PMC   4842070 . PMID   27144021.
  140. ↑ Tampi RR, Tampi DJ, Balachandran S, Srinivasan S (September 2016). "Antipsychotic use in dementia: a systematic review of benefits and risks from meta-analyses". Therapeutic Advances in Chronic Disease. 7 (5): 229–245. doi:10.1177/2040622316658463. PMC   4994396 . PMID   27583123.
  141. ↑ MacKenzie NE, Kowalchuk C, Agarwal SM, Costa-Dookhan KA, Caravaggio F, Gerretsen P, et al. (5 December 2018). "Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia". Frontiers in Psychiatry. 9: 622. doi: 10.3389/fpsyt.2018.00622 . PMC   6290646 . PMID   30568606.
  142. ↑ Mueller C, John C, Perera G, Aarsland D, Ballard C, Stewart R (January 2021). "Antipsychotic use in dementia: the relationship between neuropsychiatric symptom profiles and adverse outcomes". European Journal of Epidemiology. 36 (1): 89–101. doi:10.1007/s10654-020-00643-2. PMC   7847435 . PMID   32415541.
  143. ↑ Steinberg M, Lyketsos CG (September 2012). "Atypical antipsychotic use in patients with dementia: managing safety concerns". The American Journal of Psychiatry. 169 (9): 900–906. doi:10.1176/appi.ajp.2012.12030342. PMC   3516138 . PMID   22952071.
  144. ↑ Joint Formulary Committee B, ed. (March 2009). "4.2.1". British National Formulary (57 ed.). United Kingdom: Royal Pharmaceutical Society of Great Britain. p. 192. ISBN   978-0-85369-845-6. Withdrawal of antipsychotic drugs after long-term therapy should always be gradual and closely monitored to avoid the risk of acute withdrawal syndromes or rapid relapse.
  145. 1 2 3 4 5 Haddad P, Haddad PM, Dursun S, Deakin B (2004). Adverse Syndromes and Psychiatric Drugs: A Clinical Guide. OUP Oxford. pp. 207–216. ISBN   978-0-19-852748-0.
  146. 1 2 Moncrieff J (July 2006). "Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse". Acta Psychiatrica Scandinavica. 114 (1): 3–13. doi:10.1111/j.1600-0447.2006.00787.x. PMID   16774655. S2CID   6267180.
  147. ↑ Sacchetti E, Vita A, Siracusano A, Fleischhacker W (2013). Adherence to Antipsychotics in Schizophrenia. Springer Science & Business Media. p. 85. ISBN   978-88-470-2679-7.
  148. ↑ Nakata Y, Kanahara N, Iyo M (December 2017). "Dopamine supersensitivity psychosis in schizophrenia: Concepts and implications in clinical practice". Journal of Psychopharmacology. 31 (12): 1511–1518. doi:10.1177/0269881117728428. PMID   28925317. S2CID   1957881.
  149. ↑ Glazer WM (2000). "Expected incidence of tardive dyskinesia associated with atypical antipsychotics". The Journal of Clinical Psychiatry. 61 (Suppl 4): 21–6. PMID   10739327.
  150. ↑ Lambert TJ (2007). "Switching antipsychotic therapy: what to expect and clinical strategies for improving therapeutic outcomes". The Journal of Clinical Psychiatry. 68 (Suppl 6): 10–3. PMID   17650054.
  151. ↑ BMJ Group (March 2009). "4.2.1". British National Formulary (57 ed.). United Kingdom: Royal Pharmaceutical Society of Great Britain. p. 192. Withdrawal of antipsychotic drugs after long-term therapy should always be gradual and closely monitored to avoid the risk of acute withdrawal syndromes or rapid relapse.
  152. ↑ "Up to 100,000 on antipsychotics with no review". Health Service Journal. 27 January 2020. Retrieved 22 March 2020.
  153. ↑ Seeman P (January 2004). "Atypical Antipsychotics: Mechanism of Action". Focus. 2 (1): 48–58. doi:10.1176/foc.2.1.48.
  154. 1 2 Onrust SV, McClellan K (2001). "Perospirone". CNS Drugs. 15 (4): 329–37, discussion 338. doi:10.2165/00023210-200115040-00006. PMID   11463136. S2CID   262520276.
  155. ↑ Nemeroff CB, Lieberman JA, Weiden PJ, Harvey PD, Newcomer JW, Schatzberg AF, Kilts CD, Daniel DG (November 2005). "From clinical research to clinical practice: a 4-year review of ziprasidone". CNS Spectrums. 10 (11 Suppl 17): 1–20. doi:10.1017/S1092852900019842. PMID   16381088. S2CID   26738197.
  156. ↑ Winans E (1 December 2003). "Aripiprazole". American Journal of Health-System Pharmacy. 60 (23): 2437–2445. doi:10.1093/ajhp/60.23.2437. ISSN   1079-2082. PMID   14686220.
  157. ↑ "Caplyta (lumateperone) FDA Approval History". Drugs.com. Retrieved 20 November 2022.
  158. ↑ Swainston Harrison T, Perry CM (2004). "Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder". Drugs. 64 (15): 1715–36. doi:10.2165/00003495-200464150-00010. PMID   15257633.
  159. ↑ Pickar D, Litman RE, Konicki PE, Wolkowitz OM, Breier A (1990). "Neurochemical and Neural Mechanisms of Positive and Negative Symptoms in Schizophrenia". Modern Problems of Pharmacopsychiatry. Modern Trends in Pharmacopsychiatry. 24: 124–151. doi:10.1159/000418015. ISBN   978-3-8055-5050-5. PMID   1970851.
  160. ↑ Liemburg EJ, Knegtering H, Klein HC, Kortekaas R, Aleman A (June 2012). "Antipsychotic medication and prefrontal cortex activation: a review of neuroimaging findings". European Neuropsychopharmacology. 22 (6): 387–400. doi:10.1016/j.euroneuro.2011.12.008. PMID   22300864. S2CID   24877454.
  161. 1 2 McDonald C, Murphy KC (March 2003). "The new genetics of schizophrenia". The Psychiatric Clinics of North America. 26 (1): 41–63. doi:10.1016/S0193-953X(02)00030-8. PMID   12683259.
  162. ↑ Schmidt CJ, Sorensen SM, Kehne JH, Carr AA, Palfreyman MG (1995). "The role of 5-HT2A receptors in antipsychotic activity". Life Sciences. 56 (25): 2209–22. doi:10.1016/0024-3205(95)00210-W. PMID   7791509.
  163. ↑ Tiwari P, Panik R, Bhattacharya A, Ahirwar D, Chandy A (December 2012). "Evidences of possible side effects of neuroleptic drugs: A systematic review". Asian Pacific Journal of Reproduction. 1 (4): 330–336. doi: 10.1016/s2305-0500(13)60105-0 . ISSN   2305-0500.
  164. 1 2 Stahl SM (2003). "Describing an Atypical Antipsychotic: Receptor Binding and Its Role in Pathophysiology" (PDF). Primary Care Companion to the Journal of Clinical Psychiatry. 5 (Suppl. 3): 9–13. Archived (PDF) from the original on 9 October 2022.
  165. ↑ Meltzer HY (2012). "Serotonergic Mechanisms as Targets for Existing and Novel Antipsychotics". Current Antipsychotics. Handbook of Experimental Pharmacology. Vol. 212. pp. 87–124. doi:10.1007/978-3-642-25761-2_4. ISBN   978-3-642-25760-5. PMID   23129329.
  166. ↑ Li M (August 2016). "Antipsychotic-induced sensitization and tolerance: Behavioral characteristics, developmental impacts, and neurobiological mechanisms". Journal of Psychopharmacology. 30 (8): 749–770. doi:10.1177/0269881116654697. PMC   4944179 . PMID   27371498.
  167. ↑ Nawaratne V, McLaughlin SP, Mayer FP, Gichi Z, Mastriano A, Carvelli L (2021). "Prolonged Amphetamine Exposures Increase the Endogenous Human Dopamine Receptors 2 at the Cellular Membrane in Cells Lacking the Dopamine Transporter". Frontiers in Cellular Neuroscience. 15: 681539. doi: 10.3389/fncel.2021.681539 . PMC   8427050 . PMID   34512264.
  168. ↑ Orejarena MJ, Lanfumey L, Maldonado R, Robledo P (August 2011). "Involvement of 5-HT2A receptors in MDMA reinforcement and cue-induced reinstatement of MDMA-seeking behaviour". The International Journal of Neuropsychopharmacology. 14 (7): 927–940. doi: 10.1017/S1461145710001215 . hdl: 10230/25548 . PMID   20942998.
  169. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 Sanchez M (May 2012). Farmacología y endocrinología del comportamiento. Editorial UOC. pp. 148–149. ISBN   978-84-9788-424-2. Archived from the original on 25 November 2017.
  170. ↑ Fischer J, Ganellin CR (13 December 2006). Analogue-based Drug Discovery. John Wiley & Sons. pp. 305–. ISBN   978-3-527-60749-5.
  171. 1 2 3 Lidow MS (22 June 2000). Neurotransmitter Receptors in Actions of Antipsychotic Medications. CRC Press. pp. 23–. ISBN   978-1-4200-4177-4.
  172. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 Silvestre JS, Prous J (June 2005). "Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes". Methods and Findings in Experimental and Clinical Pharmacology. 27 (5): 289–304. doi:10.1358/mf.2005.27.5.908643. PMID   16082416.
  173. ↑ "Aripiprazole lauroxil – Alkermes". AdisInsight. Springer Nature Switzerland AG.
  174. ↑ "Asenapine". AdisInsight. Springer Nature Switzerland AG.
  175. ↑ "Blonanserin – Sumitomo Dainippon Pharma". AdisInsight. Springer Nature Switzerland AG.
  176. ↑ "Brexpiprazole – Lundbeck/Otsuka". AdisInsight. Springer Nature Switzerland AG. Archived from the original on 11 October 2016. Retrieved 27 September 2017.
  177. ↑ "Cariprazine – Gedeon Richter". AdisInsight. Springer Nature Switzerland AG. Archived from the original on 18 August 2017. Retrieved 7 May 2017.
  178. 1 2 Csernansky JG (6 December 2012). Antipsychotics. Springer Science & Business Media. pp. 360–. ISBN   978-3-642-61007-3.
  179. ↑ William Andrew Publishing (22 October 2013). Pharmaceutical Manufacturing Encyclopedia. Elsevier. pp. 1077–. ISBN   978-0-8155-1856-3.
  180. 1 2 William Andrew Publishing (22 October 2013). Pharmaceutical Manufacturing Encyclopedia. Elsevier. pp. 1102–. ISBN   978-0-8155-1856-3.
  181. ↑ Protiva M (2010). "ChemInform Abstract: Fifty Years in Chemical Drug Research". ChemInform. 23 (9): no. doi:10.1002/chin.199209338. ISSN   0931-7597.
  182. ↑ Melich H (April 1971). "[Clotepin]". Časopis lékařů českých (in Czech). 110 (17): 404–5. PMID   5576292.
  183. 1 2 Drugs Available Abroad. Gale Research. 1991. p. 52,169. ISBN   978-0-8103-7177-4. Archived from the original on 22 July 2017.
  184. ↑ Geller V, Gorzaltsan I, Shleifer T, Belmaker RH, Bersudsky Y (December 2005). "Clotiapine compared with chlorpromazine in chronic schizophrenia". Schizophrenia Research. 80 (2–3): 343–7. doi:10.1016/j.schres.2005.07.007. PMID   16126373. S2CID   22340010.
  185. ↑ Bourin M, Dailly E, Hascöet M (2004). "Preclinical and clinical pharmacology of cyamemazine: anxiolytic effects and prevention of alcohol and benzodiazepine withdrawal syndrome". CNS Drug Reviews. 10 (3): 219–29. doi:10.1111/j.1527-3458.2004.tb00023.x. PMC   6741725 . PMID   15492772.
  186. ↑ Lamberth C, Dinges J (16 August 2012). Bioactive Heterocyclic Compound Classes: Pharmaceuticals. John Wiley & Sons. pp. 3–. ISBN   978-3-527-66447-4.
  187. 1 2 Pedersen V (1996). "Thioxanthene antipsychotics". European Psychiatry. 11: 236s. doi:10.1016/0924-9338(96)88706-2. ISSN   0924-9338. S2CID   247414112.
  188. ↑ "Iloperidone – Vanda Pharmaceuticals". AdisInsight. Springer Nature Switzerland AG. Archived from the original on 11 December 2015. Retrieved 27 September 2017.
  189. 1 2 Shorter E (2009). Before Prozac: The Troubled History of Mood Disorders in Psychiatry. Oxford University Press, USA. pp. 14–. ISBN   978-0-19-536874-1.
  190. ↑ Glazer WM (1999). "Does loxapine have "atypical" properties? Clinical evidence". The Journal of Clinical Psychiatry. 60 (Suppl 10): 42–6. PMID   10340686.
  191. ↑ "Lurasidone – Sumitomo Dainippon Pharma". AdisInsight. Springer Nature Switzerland AG. Archived from the original on 10 May 2016. Retrieved 7 May 2017.
  192. ↑ "Nemonapride". AdisInsight. Springer Nature Switzerland AG.
  193. ↑ "Paliperidone – Johnson & Johnson". AdisInsight. Springer Nature Switzerland AG.
  194. ↑ "Paliperidone palmitate – Johnson & Johnson". AdisInsight. Springer Nature Switzerland AG. Archived from the original on 30 October 2016. Retrieved 27 September 2017.
  195. 1 2 Vardanyan R (12 June 2017). Piperidine-Based Drug Discovery. Elsevier Science. pp. 158, 195–. ISBN   978-0-12-813428-3.
  196. ↑ Roelofs GA (1974). "Penfluridol (R 16341) as a maintenance therapy in chronic psychotic patients: a double-blind clinical evaluation". Acta Psychiatrica Scandinavica. 50 (2): 219–24. doi:10.1111/j.1600-0447.1974.tb08210.x. PMID   4604881. S2CID   40524276.
  197. ↑ Leucht S, Helfer B, Hartung B (January 2014). "Perazine for schizophrenia". The Cochrane Database of Systematic Reviews (1): CD002832. doi:10.1002/14651858.CD002832.pub3. PMID   24425538.
  198. ↑ Matar HE, Almerie MQ, Makhoul S, Xia J, Humphreys P (May 2014). "Pericyazine for schizophrenia". The Cochrane Database of Systematic Reviews (5): CD007479. doi:10.1002/14651858.CD007479.pub2. PMID   24825770.
  199. ↑ "Perospirone". AdisInsight. Springer Nature Switzerland AG.
  200. ↑ "Pimavanserin – ACADIA Pharmaceuticals". AdisInsight. Springer Nature Switzerland AG. Archived from the original on 25 September 2017. Retrieved 27 September 2017.
  201. ↑ William Andrew Publishing (22 October 2013). Pharmaceutical Manufacturing Encyclopedia. Elsevier. pp. 2935–. ISBN   978-0-8155-1856-3.
  202. ↑ William Andrew Publishing (2007). Pharmaceutical Manufacturing Encyclopedia. William Andrew Pub. p. 3059. ISBN   978-0-8155-1526-5.
  203. ↑ William Andrew Publishing (22 October 2013). Pharmaceutical Manufacturing Encyclopedia. Elsevier. pp. 3129–. ISBN   978-0-8155-1856-3.
  204. ↑ William Andrew Publishing (22 October 2013). Pharmaceutical Manufacturing Encyclopedia. Elsevier. pp. 3214–. ISBN   978-0-8155-1856-3.
  205. ↑ Rossi, S, ed. (2013). Australian Medicines Handbook (2013 ed.). Adelaide: The Australian Medicines Handbook Unit Trust. ISBN   978-0-9805790-9-3.
  206. ↑ Joint Formulary Committee (2013). British National Formulary (BNF) (65 ed.). London, UK: Pharmaceutical Press. ISBN   978-0-85711-084-8.
  207. ↑ Isbister GK, Balit CR, Macleod D, Duffull SB (August 2010). "Amisulpride overdose is frequently associated with QT prolongation and torsades de pointes". Journal of Clinical Psychopharmacology. 30 (4): 391–5. doi:10.1097/JCP.0b013e3181e5c14c. PMID   20531221. S2CID   205710487.
  208. 1 2 3 Deeks ED, Keating GM (January 2010). "Blonanserin: a review of its use in the management of schizophrenia". CNS Drugs. 24 (1): 65–84. doi:10.2165/11202620-000000000-00000. PMID   20030420. S2CID   23464075.
  209. 1 2 Tenjin T, Miyamoto S, Ninomiya Y, Kitajima R, Ogino S, Miyake N, Yamaguchi N (2013). "Profile of blonanserin for the treatment of schizophrenia". Neuropsychiatric Disease and Treatment. 9: 587–94. doi: 10.2147/NDT.S34433 . PMC   3677929 . PMID   23766647.
  210. ↑ "Clozapine". Martindale: The Complete Drug Reference. Royal Pharmaceutical Society of Great Britain. 30 January 2013. Retrieved 2 November 2013.
  211. ↑ Matar HE, Almerie MQ, Sampson S (June 2018). "Fluphenazine (oral) versus placebo for schizophrenia". The Cochrane Database of Systematic Reviews. 2020 (7): CD006352. doi:10.1002/14651858.CD006352.pub3. PMC   3796096 . PMID   29893410.
  212. ↑ Chakrabarti A, Bagnall A, Chue P, Fenton M, Palaniswamy V, Wong W, Xia J (October 2007). Chakrabarti A (ed.). "Loxapine for schizophrenia". The Cochrane Database of Systematic Reviews. 2007 (4): CD001943. doi:10.1002/14651858.CD001943.pub2. PMC   7017975 . PMID   17943763.
  213. ↑ Harvey PD, Ogasa M, Cucchiaro J, Loebel A, Keefe RS (April 2011). "Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone". Schizophrenia Research. 127 (1–3): 188–94. doi:10.1016/j.schres.2011.01.004. PMID   21277745. S2CID   8805912.
  214. ↑ Röhricht F, Gadhia S, Alam R, Willis M (2012). "Auditing clinical outcomes after introducing off-licence prescribing of atypical antipsychotic melperone for patients with treatment refractory schizophrenia". TheScientificWorldJournal. 2012: 1–5. doi: 10.1100/2012/512047 . PMC   3330679 . PMID   22566771.
  215. 1 2 "Molindone Hydrochloride". Martindale: The Complete Drug Reference. The Royal Pharmaceutical Society of Great Britain. 30 January 2013. Retrieved 5 November 2013.
  216. ↑ Leucht S, Helfer B, Hartung B (January 2014). "Perazine for schizophrenia". The Cochrane Database of Systematic Reviews (1): CD002832. doi:10.1002/14651858.CD002832.pub3. PMID   24425538.
  217. ↑ Onrust SV, McClellan K (April 2001). "Perospirone". CNS Drugs. 15 (4): 329–37, discussion 338. doi:10.2165/00023210-200115040-00006. PMID   11463136. S2CID   262520276.
  218. 1 2 Brayfield A, ed. (23 September 2011). "Perospirone". Martindale: The Complete Drug Reference. London, UK: Pharmaceutical Press. Retrieved 3 November 2013.
  219. ↑ Hartung B, Sampson S, Leucht S (March 2015). "Perphenazine for schizophrenia". The Cochrane Database of Systematic Reviews. 2015 (3): CD003443. doi:10.1002/14651858.CD003443.pub3. PMC   7173727 . PMID   25749632.
  220. ↑ Mothi M, Sampson S (November 2013). "Pimozide for schizophrenia or related psychoses". The Cochrane Database of Systematic Reviews (11): CD001949. doi:10.1002/14651858.CD001949.pub3. PMID   24194433.
  221. ↑ Wang J, Sampson S (April 2014). "Sulpiride versus placebo for schizophrenia". The Cochrane Database of Systematic Reviews (4): CD007811. doi:10.1002/14651858.CD007811.pub2. PMID   24729184.
  222. ↑ Fenton M, Rathbone J, Reilly J, Sultana A (July 2007). Reilly J (ed.). "Thioridazine for schizophrenia". The Cochrane Database of Systematic Reviews. 2007 (3): CD001944. doi:10.1002/14651858.CD001944.pub2. PMC   6718212 . PMID   17636691.
  223. ↑ Fornaro P, Calabria G, Corallo G, Picotti GB (July 2002). "Pathogenesis of degenerative retinopathies induced by thioridazine and other antipsychotics: a dopamine hypothesis". Documenta Ophthalmologica. Advances in Ophthalmology. 105 (1): 41–9. doi:10.1023/A:1015768114192. PMID   12152801. S2CID   23618581.
  224. ↑ Marques LO, Lima MS, Soares BG (2004). de Oliveira Marques L (ed.). "Trifluoperazine for schizophrenia". The Cochrane Database of Systematic Reviews. 2004 (1): CD003545. doi:10.1002/14651858.CD003545.pub2. PMC   7003674 . PMID   14974020.
  225. ↑ "Zotepine". Martindale: The Complete Drug Reference. Royal Pharmaceutical Society of Great Britain. 16 August 2013. Retrieved 2 November 2013.
  226. ↑ Cipriani A, Barbui C, Salanti G, Rendell J, Brown R, Stockton S, et al. (October 2011). "Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis". Lancet. 378 (9799): 1306–1315. doi:10.1016/S0140-6736(11)60873-8. PMID   21851976. S2CID   25512763.
  227. ↑ Citrome L (2013). "Addressing the need for rapid treatment of agitation in schizophrenia and bipolar disorder: focus on inhaled loxapine as an alternative to injectable agents". Therapeutics and Clinical Risk Management. 9: 235–245. doi: 10.2147/TCRM.S31484 . PMC   3665578 . PMID   23723707.
  228. ↑ Cruz N, Sanchez-Moreno J, Torres F, Goikolea JM, Valentí M, Vieta E (February 2010). "Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis". The International Journal of Neuropsychopharmacology. 13 (1): 5–14. doi: 10.1017/S1461145709990344 . hdl: 2445/53243 . PMID   19638254.
  229. ↑ Popovic D, Reinares M, Goikolea JM, Bonnin CM, Gonzalez-Pinto A, Vieta E (May 2012). "Polarity index of pharmacological agents used for maintenance treatment of bipolar disorder". European Neuropsychopharmacology. 22 (5): 339–346. doi:10.1016/j.euroneuro.2011.09.008. PMID   22000157. S2CID   8067809.
  230. ↑ Vieta E, Günther O, Locklear J, Ekman M, Miltenburger C, Chatterton ML, et al. (September 2011). "Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: a meta-analysis of randomized controlled trials". The International Journal of Neuropsychopharmacology. 14 (8): 1029–1049. doi:10.1017/S1461145711000885. hdl: 2445/51726 . PMID   21733231.
  231. ↑ Komossa K, Depping AM, Gaudchau A, Kissling W, Leucht S (December 2010). "Second-generation antipsychotics for major depressive disorder and dysthymia". The Cochrane Database of Systematic Reviews (12): CD008121. doi:10.1002/14651858.CD008121.pub2. PMID   21154393.
  232. ↑ Arafat SM, Rahman SM, Haque MM, Shah MA, Algin S, Nahar JS (2016). "Clozapine Can Be the Good Option in Resistant Mania". Case Reports in Psychiatry. 2016: 3081704. doi: 10.1155/2016/3081704 . PMC   4976188 . PMID   27525148.
  233. ↑ Wilkowska A, Cubała WJ (9 October 2019). "Clozapine As Transformative Treatment In Bipolar Patients". Neuropsychiatric Disease and Treatment. 15: 2901–2905. doi: 10.2147/NDT.S227196 . PMC   6790347 . PMID   31632038.
  234. ↑ https://www.has-sante.fr/upload/docs/application/pdf/2012-04/anti_psychotiques_rapport.pdf%5B%5D
  235. ↑ Kishi T, Iwata N (September 2013). "Efficacy and tolerability of perospirone in schizophrenia: a systematic review and meta-analysis of randomized controlled trials". CNS Drugs. 27 (9): 731–41. doi:10.1007/s40263-013-0085-7. PMID   23812802. S2CID   11543666.
  236. ↑ Roth BL, Driscol J (12 January 2011). "PDSP Ki Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Archived from the original on 8 November 2013. Retrieved 11 November 2013.
  237. ↑ Shahid M, Walker GB, Zorn SH, Wong EH (January 2009). "Asenapine: a novel psychopharmacologic agent with a unique human receptor signature". Journal of Psychopharmacology. 23 (1): 65–73. doi:10.1177/0269881107082944. PMID   18308814. S2CID   206489515.
  238. 1 2 Ishiyama T, Tokuda K, Ishibashi T, Ito A, Toma S, Ohno Y (October 2007). "Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test". European Journal of Pharmacology. 572 (2–3): 160–70. doi:10.1016/j.ejphar.2007.06.058. PMID   17662268.
  239. ↑ Ishibashi T, Horisawa T, Tokuda K, Ishiyama T, Ogasa M, Tagashira R, Matsumoto K, Nishikawa H, Ueda Y, Toma S, Oki H, Tanno N, Saji I, Ito A, Ohno Y, Nakamura M (July 2010). "Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity". The Journal of Pharmacology and Experimental Therapeutics. 334 (1): 171–81. doi:10.1124/jpet.110.167346. PMID   20404009. S2CID   12893717.
  240. ↑ López-Muñoz F, Alamo C (September 2013). "Active metabolites as antidepressant drugs: the role of norquetiapine in the mechanism of action of quetiapine in the treatment of mood disorders". Frontiers in Psychiatry. 4: 102. doi: 10.3389/fpsyt.2013.00102 . PMC   3770982 . PMID   24062697.
  241. ↑ "Medscape home page". Medscape . WebMD. Archived from the original on 13 November 2013.
  242. ↑ "Therapeutic Goods Administration home page". Therapeutic Goods Administration . Department of Health (Australia). Archived from the original on 21 April 2013.
  243. ↑ "Daily Med home page". Daily Med . United States National Library of Medicine. Archived from the original on 18 June 2013.
  244. ↑ "electronic Medicines Compendium (eMC) home page". electronic Medicines Compendium. Datapharm. Archived from the original on 27 November 2013.
  245. ↑ Wen YG, Shang DW, Xie HZ, Wang XP, Ni XJ, Zhang M, Lu W, Qiu C, Liu X, Li FF, Li X, Luo FT (March 2013). "Population pharmacokinetics of blonanserin in Chinese healthy volunteers and the effect of the food intake". Human Psychopharmacology. 28 (2): 134–41. doi:10.1002/hup.2290. PMID   23417765. S2CID   12623938.
  246. ↑ Borgström L, Larsson H, Molander L (1982). "Pharmacokinetics of parenteral and oral melperone in man". European Journal of Clinical Pharmacology. 23 (2): 173–6. doi:10.1007/BF00545974. PMID   7140807. S2CID   36697288.
  247. ↑ Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM (September 1999). "Olanzapine. Pharmacokinetic and pharmacodynamic profile". Clinical Pharmacokinetics. 37 (3): 177–93. doi:10.2165/00003088-199937030-00001. PMID   10511917.
  248. ↑ Vermeir M, Naessens I, Remmerie B, Mannens G, Hendrickx J, Sterkens P, Talluri K, Boom S, Eerdekens M, van Osselaer N, Cleton A (April 2008). "Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans". Drug Metabolism and Disposition. 36 (4): 769–79. doi:10.1124/dmd.107.018275. PMID   18227146. S2CID   41656.
  249. ↑ DeVane CL, Nemeroff CB (2001). "Clinical pharmacokinetics of quetiapine: an atypical antipsychotic". Clinical Pharmacokinetics. 40 (7): 509–22. doi:10.2165/00003088-200140070-00003. PMID   11510628. S2CID   33802262.
  250. ↑ Wiesel FA, Alfredsson G, Ehrnebo M, Sedvall G (May 1980). "The pharmacokinetics of intravenous and oral sulpiride in healthy human subjects". European Journal of Clinical Pharmacology. 17 (5): 385–91. doi:10.1007/BF00558453. PMID   7418717. S2CID   28141135.
  251. ↑ Prakash A, Lamb HM (January 1998). "Zotepine: A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Efficacy in the Management of Schizophrenia". CNS Drugs. 9 (2): 153–175. doi:10.2165/00023210-199809020-00006.
  252. ↑ Product Information: Nipolept(R), zotepine. Klinge Pharma GmbH, Munich, 1996.
  253. ↑ Parent M, Toussaint C, Gilson H (1983). "Long-term treatment of chronic psychotics with bromperidol decanoate: clinical and pharmacokinetic evaluation". Current Therapeutic Research. 34 (1): 1–6.
  254. 1 2 Jørgensen A, Overø KF (1980). "Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. III. Serum levels". Acta Psychiatrica Scandinavica. Supplementum. 279: 41–54. doi:10.1111/j.1600-0447.1980.tb07082.x. PMID   6931472.
  255. 1 2 Reynolds JE (1993). "Anxiolytic sedatives, hypnotics and neuroleptics.". Martindale: The Extra Pharmacopoeia (30th ed.). London: Pharmaceutical Press. pp. 364–623.
  256. ↑ Ereshefsky L, Saklad SR, Jann MW, Davis CM, Richards A, Seidel DR (May 1984). "Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches". The Journal of Clinical Psychiatry. 45 (5 Pt 2): 50–9. PMID   6143748.
  257. 1 2 Curry SH, Whelpton R, de Schepper PJ, Vranckx S, Schiff AA (April 1979). "Kinetics of fluphenazine after fluphenazine dihydrochloride, enanthate and decanoate administration to man". British Journal of Clinical Pharmacology. 7 (4): 325–31. doi:10.1111/j.1365-2125.1979.tb00941.x. PMC   1429660 . PMID   444352.
  258. ↑ Young D, Ereshefsky L, Saklad SR, Jann MW, Garcia N (1984). Explaining the pharmacokinetics of fluphenazine through computer simulations. (Abstract.). 19th Annual Midyear Clinical Meeting of the American Society of Hospital Pharmacists. Dallas, Texas.
  259. ↑ Janssen PA, Niemegeers CJ, Schellekens KH, Lenaerts FM, Verbruggen FJ, van Nueten JM, Marsboom RH, Hérin VV, Schaper WK (November 1970). "The pharmacology of fluspirilene (R 6218), a potent, long-acting and injectable neuroleptic drug". Arzneimittel-Forschung. 20 (11): 1689–98. PMID   4992598.
  260. ↑ Beresford R, Ward A (January 1987). "Haloperidol decanoate. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis". Drugs. 33 (1): 31–49. doi:10.2165/00003495-198733010-00002. PMID   3545764.
  261. ↑ Reyntigens AJ, Heykants JJ, Woestenborghs RJ, Gelders YG, Aerts TJ (1982). "Pharmacokinetics of haloperidol decanoate. A 2-year follow-up". International Pharmacopsychiatry. 17 (4): 238–46. doi:10.1159/000468580. PMID   7185768.
  262. ↑ Larsson M, Axelsson R, Forsman A (1984). "On the pharmacokinetics of perphenazine: a clinical study of perphenazine enanthate and decanoate". Current Therapeutic Research. 36 (6): 1071–88.
  263. ↑ The text reads: "When the patient lashes out against 'them' – THORAZINE (brand of chlorpromazine) quickly puts an end to his violent outburst. 'Thorazine' is especially effective when the psychotic episode is triggered by delusions or hallucinations. At the outset of treatment, Thorazine's combination of antipsychotic and sedative effects provides both emotional and physical calming. Assaultive or destructive behavior is rapidly controlled. As therapy continues, the initial sedative effect gradually disappears. But the antipsychotic effect continues, helping to dispel or modify delusions, hallucinations and confusion, while keeping the patient calm and approachable. SMITH KLINE AND FRENCH LABORATORIES leaders in psychopharmaceutical research."
  264. 1 2 Pieters T, Majerus B (December 2011). "The introduction of chlorpromazine in Belgium and the Netherlands (1951–1968); tango between old and new treatment features". Studies in History and Philosophy of Biological and Biomedical Sciences. 42 (4): 443–452. doi:10.1016/j.shpsc.2011.05.003. PMID   22035718. Archived from the original on 9 July 2017. Retrieved 26 February 2017.
  265. ↑ Healy D (2005). Psychiatric Drugs Explained (4th ed.). Britain: Elsevier Limited. pp. 8, 17.
  266. ↑ "tranquillizer, n". Oxford English Dictionary. 1989. Retrieved 9 August 2011.
  267. ↑ Healy D (2008). "The Intersection of Psychopharmacology and Psychiatry in the Second Half of the Twentieth Century". In Wallace ER, Gach J (eds.). History of Psychiatry and Medical Psychology. Boston, MA: Springer US. p. 421. doi:10.1007/978-0-387-34708-0_13. ISBN   978-0-387-34707-3.
  268. ↑ Owens DG (13 April 1999). A guide to the extrapyramidal side-effects of antipsychotic drugs. Cambridge University Press. p. 12. ISBN   978-0-521-63353-6. Archived from the original on 18 March 2016.
  269. ↑ Wilson S, Anderson K, Baldwin D, Dijk DJ, Espie A, Espie C, et al. (August 2019). "British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: An update". Journal of Psychopharmacology. 33 (8): 923–947. doi:10.1177/0269881119855343. PMID   31271339. S2CID   195797603.
  270. ↑ Tasman A (1997). Psychiatry Volume 2. Saunders. p. 956. ISBN   978-0-7216-5257-3.
  271. ↑ Ayd FJ (2000). "neuroleptic". Lexicon of Psychiatry, Neurology, and the Neurosciences. Lippincott Williams & Wilkins. p. 675. ISBN   978-0-7817-2468-5.
  272. ↑ R. Elliott Ingersoll, Carl F. Rak (2015): Psychopharmacology for Mental Health Professionals: An Integrative Approach, Cengage Learning, Boston, pp. 150-186 and 342-349, ISBN   9781305537231.
  273. ↑ Patel SC, Jakopac KA (2011). Manual of Psychiatric Nursing Skills. Jones & Bartlett Publishers. p. 317. ISBN   978-1-4496-1356-3.
  274. ↑ Drug Policy and the Public Good. OUP Oxford. 2010. p. 329. ISBN   978-0-19-955712-7.
  275. 1 2 Pipelineantipsychotic drugs to drive next market evolution (2009). Healthcarefinancenews.com (7 August 2009).
  276. ↑ Aparasu RR, Bhatara V (December 2006). "Antipsychotic use and expenditure in the United States". Psychiatric Services. 57 (12): 1693. doi:10.1176/appi.ps.57.12.1693. PMID   17158480.
  277. ↑ 2008 U.S. Sales and Prescription Information: Top Therapeutic Classes by U.S. Sales (PDF) Archived 16 April 2010 at the Wayback Machine . Imshealth.com.
  278. ↑ "Data show 'spiralling' antipsychotic price increases of up to 1,200% in past five years". Pharmaceutical Journal. 24 August 2022. Retrieved 29 September 2022.
  279. ↑ Gustafsson M, Karlsson S, Lövheim H (February 2013). "Inappropriate long-term use of antipsychotic drugs is common among people with dementia living in specialized care units". BMC Pharmacology & Toxicology. 14 (1): 10. doi: 10.1186/2050-6511-14-10 . PMC   3575309 . PMID   23391323.
  280. ↑ Risky Antipsychotic Drugs Still Overprescribed In Nursing Homes, https://www.npr.org/sections/health-shots/2018/02/05/583435517/risky-antipsychotic-drugs-still-overprescribed-in-nursing-homes
  281. ↑ Atypical antipsychotics: overrated and overprescribed, Glen Spielsman, https://pharmaceutical-journal.com/article/opinion/atypical-antipsychotics-overrated-and-overprescribed
  282. ↑ Carrithers B, El-Mallakh RS (18 March 2020). "Transdermal Asenapine in Schizophrenia: A Systematic Review". Patient Preference and Adherence. 14: 1541–1551. doi: 10.2147/PPA.S235104 . PMC   7468370 . PMID   32943849.
  283. 1 2 3 4 5 Bogart G (2011). "Abuse of second-generation antipsychotics: What prescribers need to know". Current Psychiatry. 10 (5): 77–79.
  284. ↑ James A (2 March 2008). "Myth of the antipsychotic". The Guardian.
  285. ↑ "GPs under 'pressure' to issue neuroleptics, claims professor". Chemist+Druggist.[ unreliable source? ]
  286. ↑ Triggle N (12 November 2009). "Dementia drug use 'killing many'".
  287. ↑ "UK study warns against anti-psychotics for dementia". Reuters. 12 November 2009.
  288. ↑ Hilzenrath DS (16 January 2010). "Justice suit accuses Johnson & Johnson of paying kickbacks". The Washington Post .
  289. 1 2 3 Wilson D (2 October 2010). "Side Effects May Include Lawsuits". The New York Times. Archived from the original on 5 October 2010.
  290. ↑ Wilson D (27 February 2009). "Drug Maker's E-Mail Released in Seroquel Lawsuit". The New York Times.
  291. ↑ Gosden R, Beder S (1 January 2001). "Pharmaceutical industry agenda setting in mental health policies". Ethical Human Sciences and Services. 3 (3): 147–159. doi:10.1891/1523-150X.3.3.147 (inactive 31 January 2024). PMID   15278977.{{cite journal}}: CS1 maint: DOI inactive as of January 2024 (link)
  292. 1 2 3 American Psychiatric Association (September 2013). "Five Things Physicians and Patients Should Question". Choosing Wisely: an initiative of the ABIM Foundation . American Psychiatric Association. Archived from the original on 3 December 2013. Retrieved 30 December 2013., which cites
  293. ↑ American Geriatrics Society. "Ten Things Physicians and Patients Should Question". Choosing Wisely: an initiative of the ABIM Foundation . American Geriatrics Society. Archived from the original on 1 September 2013. Retrieved 1 August 2013., which cites

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.